Listing 16.2.5-PCL (Page 1 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)	
MOON/100100	25/F/Ca	1	A	2012-10-30T08:18	1	0	2012-10-30T08:11	0	0	(<20)
						0.25	2012-10-30T08:33	0.25	260	
						0.5	2012-10-30T08:48	0.5	3030	
						1	2012-10-30T09:19	1.016	14700	
						1.5	2012-10-30T09:48	1.5	23900	
						12	2012-10-30T20:18	12	7420	
						2	2012-10-30T10:18	2	26400	
						3	2012-10-30T11:18	3	23200	
						4	2012-10-30T12:20	4.033	19600	
						6	2012-10-30T14:21	6.05	13500	
						8	2012-10-30T16:18	8	10300	
					2	24	2012-10-31T08:41	24.38	3360	
					3	48	2012-11-01T08:22	48.06	808	
					4	72	2012-11-02T08:18	72	223	
					5	96	2012-11-03T08:20	96.03	72.6	
		3	C	2012-11-08T08:18	1	0	2012-11-08T08:08	0	0	(<20)
						0.25	2012-11-08T08:33	0.25	0	(<20)
						0.5	2012-11-08T08:49	0.516	331	
						1	2012-11-08T09:17	0.983	4290	
						1.5	2012-11-08T09:48	1.5	9140	
						12	2012-11-08T20:18	12	7050	

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 2 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Treatment Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)	
MOON/100100	25/F/Ca	3	C	2012-11-08T08:18	1	2	2012-11-08T10:18	2	13300	
						3	2012-11-08T11:21	3.05	18100	
						4	2012-11-08T12:20	4.033	19700	
						6	2012-11-08T14:18	6	14000	
						8	2012-11-08T16:18	8	10400	
					2	24	2012-11-09T08:18	24	2840	
					3	48	2012-11-10T08:18	48	617	
					4	72	2012-11-11T08:18	72	178	
					5	96	2012-11-12T08:20	96.03	57	
MOON/100100	25/F/Ca	1	A	2012-10-30T08:23	1	0	2012-10-30T08:15	0	0	(<20)
						0.25	2012-10-30T08:38	0.25	0	(<20)
						0.5	2012-10-30T08:54	0.516	786	
						1	2012-10-30T09:23	1	4070	
						1.5	2012-10-30T09:53	1.5	6740	
						12	2012-10-30T20:23	12	3340	
						2	2012-10-30T10:23	2	6960	
						3	2012-10-30T11:23	3	7670	
						4	2012-10-30T12:23	4	7920	
						6	2012-10-30T14:24	6.016	5880	
						8	2012-10-30T16:23	8	4930	

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 3 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100100	25/F/Ca	1	A	2012-10-30T08:23	2	24	2012-10-31T08:25	24.03	1200
					3	48	2012-11-01T08:24	48.01	246
					4	72	2012-11-02T08:23	72	47.7
					5	96	2012-11-03T08:23	96	0 (<20)
		3	C	2012-11-08T08:23	1	0	2012-11-08T08:13	0	0 (<20)
						0.25	2012-11-08T08:38	0.25	0 (<20)
						0.5	2012-11-08T08:55	0.533	220
						1	2012-11-08T09:23	1	1870
						1.5	2012-11-08T09:53	1.5	5310
						12	2012-11-08T20:23	12	3610
						2	2012-11-08T10:23	2	8670
						3	2012-11-08T11:23	3	11500
						4	2012-11-08T12:24	4.016	9930
						6	2012-11-08T14:23	6	6720
						8	2012-11-08T16:23	8	5220
					2	24	2012-11-09T08:23	24	1470
					3	48	2012-11-10T08:24	48.01	213
					4	72	2012-11-11T08:23	72	42.8
					5	96	2012-11-12T08:24	96.01	0 (<20)
MOON/100100	25/F/Ca	1	A	2012-10-30T08:15	1	0	2012-10-30T08:05	0	0 (<20)

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 4 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100100	25/F/Ca	1	A	2012-10-30T08:15	1	0.25	2012-10-30T08:31	0.266	48
						0.5	2012-10-30T08:45	0.5	1020
						1	2012-10-30T09:15	1	7020
						1.5	2012-10-30T09:45	1.5	13500
						12	2012-10-30T20:15	12	3310
						2	2012-10-30T10:15	2	16200
						3	2012-10-30T11:15	3	15200
						4	2012-10-30T12:15	4	11300
						6	2012-10-30T14:15	6	7810
						8	2012-10-30T16:15	8	5900
					2	24	2012-10-31T08:15	24	1080
					3	48	2012-11-01T08:15	48	143
					4	72	2012-11-02T08:15	72	31
					5	96	2012-11-03T08:15	96	0 (<20)
		3	C	2012-11-08T08:15	1	0	2012-11-08T08:05	0	0 (<20)
						0.25	2012-11-08T08:30	0.25	28.4
						0.5	2012-11-08T08:45	0.5	882
						1	2012-11-08T09:15	1	11400
						1.5	2012-11-08T09:45	1.5	19200
						12	2012-11-08T20:15	12	3880
						2	2012-11-08T10:15	2	21700

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 5 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100100	25/F/Ca	3	C	2012-11-08T08:15	1	3	2012-11-08T11:15	3	16700
						4	2012-11-08T12:15	4	14000
						6	2012-11-08T14:15	6	8750
						8	2012-11-08T16:15	8	6820
					2	24	2012-11-09T08:15	24	1220
					3	48	2012-11-10T08:15	48	148
					4	72	2012-11-11T08:15	72	24.5
					5	96	2012-11-12T08:15	96	0 (<20)
MOON/100100	25/F/Ca	1	A	2012-10-30T08:12	1	0	2012-10-30T08:02	0	0 (<20)
						0.25	2012-10-30T08:28	0.266	330
						0.5	2012-10-30T08:42	0.5	2930
						1	2012-10-30T09:12	1	14100
						1.5	2012-10-30T09:42	1.5	17600
						12	2012-10-30T20:12	12	5080
						2	2012-10-30T10:12	2	17600
						3	2012-10-30T11:12	3	16100
						4	2012-10-30T12:13	4.016	14100
						6	2012-10-30T14:14	6.033	10200
						8	2012-10-30T16:12	8	7960
					2	24	2012-10-31T08:12	24	1690

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 6 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100100	25/F/Ca	1	A	2012-10-30T08:12	3	48	2012-11-01T08:14	48.03	257
					4	72	2012-11-02T08:16	72.06	50
					5	96	2012-11-03T08:12	96	0 (<20)
MOON/100100	25/F/Ca	1	A	2012-10-30T08:04	1	0	2012-10-30T07:55	0	0 (<20)
						0.25	2012-10-30T08:19	0.25	35.7
						0.5	2012-10-30T08:34	0.5	465
						1	2012-10-30T09:04	1	4310
						1.5	2012-10-30T09:34	1.5	11100
						12	2012-10-30T20:04	12	3550
						2	2012-10-30T10:05	2.016	17800
						3	2012-10-30T11:04	3	17800
						4	2012-10-30T12:04	4	14700
						6	2012-10-30T14:04	6	8970
						8	2012-10-30T16:04	8	6600
					2	24	2012-10-31T08:04	24	959
					3	48	2012-11-01T08:04	48	94.6
					4	72	2012-11-02T08:04	72	0 (<20)
					5	96	2012-11-03T08:04	96	0 (<20)
		3	C	2012-11-08T08:05	1	0	2012-11-08T07:54	0	0 (<20)
						0.25	2012-11-08T08:19	0.233	252

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 7 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Treatment Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)	
MOON/100100	25/F/Ca	3	C	2012-11-08T08:05	1	0.5	2012-11-08T08:34	0.483	4550	
						1	2012-11-08T09:05	1	16500	
						1.5	2012-11-08T09:35	1.5	19100	
						12	2012-11-08T20:05	12	3160	
						2	2012-11-08T10:05	2	17900	
						3	2012-11-08T11:04	2.983	14600	
						4	2012-11-08T12:04	3.983	11900	
						6	2012-11-08T14:05	6	7680	
						8	2012-11-08T16:05	8	5330	
					2	24	2012-11-09T08:05	24	1060	
					3	48	2012-11-10T08:04	47.98	136	
					4	72	2012-11-11T08:04	71.98	38.7	
					5	96	2012-11-12T08:04	95.98	0	(<20)
MOON/100100	25/F/Ca	1	A	2012-10-30T08:10	1	0	2012-10-30T08:00	0	0	(<20)
						0.25	2012-10-30T08:25	0.25	0	(<20)
						0.5	2012-10-30T08:40	0.5	274	
						1	2012-10-30T09:10	1	2960	
						1.5	2012-10-30T09:40	1.5	6290	
						12	2012-10-30T20:10	12	4910	
						2	2012-10-30T10:10	2	10200	

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 8 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100100	25/F/Ca	1	A	2012-10-30T08:10	1	3	2012-10-30T11:11	3.016	16100
						4	2012-10-30T12:10	4	14400
						6	2012-10-30T14:10	6	9570
						8	2012-10-30T16:10	8	7220
					2	24	2012-10-31T08:10	24	2110
					3	48	2012-11-01T08:10	48	499
					4	72	2012-11-02T08:10	72	118
					5	96	2012-11-03T08:10	96	35.4
		3	C	2012-11-08T08:11	1	0	2012-11-08T08:00	0	0 (<20)
						0.25	2012-11-08T08:26	0.25	0 (<20)
						0.5	2012-11-08T08:42	0.516	182
						1	2012-11-08T09:10	0.983	2580
						1.5	2012-11-08T09:41	1.5	7330
						12	2012-11-08T20:11	12	5180
						2	2012-11-08T10:11	2	11800
						3	2012-11-08T11:10	2.983	16300
						4	2012-11-08T12:11	4	14400
						6	2012-11-08T14:11	6	9850
						8	2012-11-08T16:12	8.016	7990
					2	24	2012-11-09T08:11	24	2090
					3	48	2012-11-10T08:11	48	427

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 9 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Treatment Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100100	25/F/Ca	3	C	2012-11-08T08:11	4	72	2012-11-11T08:11	72	101
					5	96	2012-11-12T08:11	96	34.6
MOON/100100	25/F/Ca	1	A	2012-10-30T08:24	1	0	2012-10-30T08:15	0	0 (<20)
						0.25	2012-10-30T08:39	0.25	0 (<20)
						0.5	2012-10-30T08:55	0.516	553
						1	2012-10-30T09:24	1	5930
						1.5	2012-10-30T09:54	1.5	8450
						12	2012-10-30T20:24	12	2820
						2	2012-10-30T10:24	2	11400
						3	2012-10-30T11:27	3.05	14400
						4	2012-10-30T12:26	4.033	12700
						6	2012-10-30T14:24	6	7520
						8	2012-10-30T16:24	8	4710
					2	24	2012-10-31T08:26	24.03	855
					3	48	2012-11-01T08:25	48.01	111
					4	72	2012-11-02T08:24	72	27.8
					5	96	2012-11-03T08:24	96	0 (<20)
		3	C	2012-11-08T08:25	1	0	2012-11-08T08:14	0	0 (<20)
						0.25	2012-11-08T08:40	0.25	35.9
						0.5	2012-11-08T08:58	0.55	3260

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 10 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100100	25/F/Ca	3	C	2012-11-08T08:25	1	1	2012-11-08T09:25	1	10900
						1.5	2012-11-08T09:55	1.5	16300
						2	2012-11-08T10:26	2.016	14100
						3	2012-11-08T11:26	3.016	13100
						4	2012-11-08T12:26	4.016	10800
						6	2012-11-08T14:25	6	6790
						8	2012-11-08T16:25	8	4580
					2	24	2012-11-09T08:25	24	845
					3	48	2012-11-10T08:25	48	111
					4	72	2012-11-11T08:25	72	29.2
					5	96	2012-11-12T08:25	96	0 (<20)
MOON/100100	25/F/Ca	1	A	2012-10-30T08:25	1	0	2012-10-30T08:16	0	0 (<20)
						0.25	2012-10-30T08:40	0.25	105
						0.5	2012-10-30T08:55	0.5	2450
						1	2012-10-30T09:25	1	13100
						1.5	2012-10-30T09:55	1.5	18000
						12	2012-10-30T20:25	12	5010
						2	2012-10-30T10:25	2	17300
						3	2012-10-30T11:25	3	16300
						4	2012-10-30T12:25	4	13300

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 11 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100100	25/F/Ca	1	A	2012-10-30T08:25	1	6	2012-10-30T14:25	6	9650
						8	2012-10-30T16:26	8.016	7910
					2	24	2012-10-31T08:27	24.03	1930
					3	48	2012-11-01T08:25	48	324
					4	72	2012-11-02T08:25	72	94.2
					5	96	2012-11-03T08:25	96	27.6
		3	C	2012-11-08T08:25	1	0	2012-11-08T08:15	0	0 (<20)
						0.25	2012-11-08T08:41	0.266	60.1
						0.5	2012-11-08T08:56	0.516	1910
						1	2012-11-08T09:25	1	14100
						1.5	2012-11-08T09:55	1.5	17300
						12	2012-11-08T20:26	12.01	4680
						2	2012-11-08T10:25	2	18700
						3	2012-11-08T11:25	3	16500
						4	2012-11-08T12:25	4	13000
						6	2012-11-08T14:25	6	9960
						8	2012-11-08T16:26	8.016	7360
					2	24	2012-11-09T08:26	24.01	1640
					3	48	2012-11-10T08:25	48	316
					4	72	2012-11-11T08:25	72	81.5
					5	96	2012-11-12T08:25	96	36.8

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 12 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100100	25/F/Ca	1	A	2012-10-30T08:14	1	0	2012-10-30T08:04	0	0 (<20)
						0.25	2012-10-30T08:29	0.25	488
						0.5	2012-10-30T08:44	0.5	5790
						1	2012-10-30T09:14	1	18900
						1.5	2012-10-30T09:44	1.5	22300
						12	2012-10-30T20:14	12	4650
						2	2012-10-30T10:14	2	18400
						3	2012-10-30T11:14	3	16700
						4	2012-10-30T12:14	4	13200
						6	2012-10-30T14:14	6	9220
						8	2012-10-30T16:14	8	7570
					2	24	2012-10-31T08:14	24	1710
					3	48	2012-11-01T08:14	48	285
					4	72	2012-11-02T08:14	72	68.8
					5	96	2012-11-03T08:14	96	21.9
		3	C	2012-11-08T08:14	1	0	2012-11-08T08:04	0	0 (<20)
						0.25	2012-11-08T08:29	0.25	283
						0.5	2012-11-08T08:44	0.5	3200
						1	2012-11-08T09:14	1	10700
						1.5	2012-11-08T09:44	1.5	16100
						12	2012-11-08T20:14	12	4480

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 13 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Treatment Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100100	25/F/Ca	3	C	2012-11-08T08:14	1	2	2012-11-08T10:14	2	17800
						3	2012-11-08T11:14	3	16200
						4	2012-11-08T12:14	4	13800
						6	2012-11-08T14:14	6	9420
						8	2012-11-08T16:14	8	7110
					2	24	2012-11-09T08:14	24	1660
					3	48	2012-11-10T08:14	48	262
					4	72	2012-11-11T08:15	72.01	71.2
					5	96	2012-11-12T08:14	96	30.8
MOON/100101	25/F/Ca	1	A	2012-10-30T08:08	1	0	2012-10-30T07:58	0	0 (<20)
						0.25	2012-10-30T08:23	0.25	144
						0.5	2012-10-30T08:38	0.5	3270
						1	2012-10-30T09:08	1	13000
						1.5	2012-10-30T09:38	1.5	17500
						12	2012-10-30T20:08	12	4400
						2	2012-10-30T10:08	2	16600
						3	2012-10-30T11:08	3	15400
						4	2012-10-30T12:08	4	12100
						6	2012-10-30T14:08	6	8730
						8	2012-10-30T16:08	8	6650

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 14 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Treatment Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)	
MOON/100101	25/F/Ca	1	A	2012-10-30T08:08	2	24	2012-10-31T08:08	24	1750	
					3	48	2012-11-01T08:08	48	271	
					4	72	2012-11-02T08:08	72	52.9	
					5	96	2012-11-03T08:08	96	0	(<20)
		3	C	2012-11-08T08:10	1	0	2012-11-08T07:59	0	0	(<20)
						0.25	2012-11-08T08:24	0.233	332	
						0.5	2012-11-08T08:39	0.483	4370	
						1	2012-11-08T09:10	1	14800	
						1.5	2012-11-08T09:41	1.516	17500	
						12	2012-11-08T20:09	11.98	4850	
						2	2012-11-08T10:10	2	17100	
						3	2012-11-08T11:10	3	14900	
						4	2012-11-08T12:11	4.016	12700	
						6	2012-11-08T14:10	6	9780	
						8	2012-11-08T16:10	8	7230	
					2	24	2012-11-09T08:10	24	1960	
					3	48	2012-11-10T08:10	48	386	
					4	72	2012-11-11T08:09	71.98	82.7	
					5	96	2012-11-12T08:10	96	23.4	
MOON/100101	25/F/Ca	1	A	2012-10-30T08:26	1	0	2012-10-30T08:16	0	0	(<20)

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 15 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)	
MOON/100101	25/F/Ca	1	A	2012-10-30T08:26	1	0.25	2012-10-30T08:42	0.266	36.6	
						0.5	2012-10-30T08:59	0.55	2010	
						1	2012-10-30T09:27	1.016	11600	
						1.5	2012-10-30T09:56	1.5	18200	
						12	2012-10-30T20:26	12	3620	
						2	2012-10-30T10:26	2	18000	
						3	2012-10-30T11:26	3	16500	
						4	2012-10-30T12:27	4.016	12800	
						6	2012-10-30T14:26	6	8920	
						8	2012-10-30T16:26	8	6130	
					2	24	2012-10-31T08:28	24.03	1220	
					3	48	2012-11-01T08:26	48	193	
					4	72	2012-11-02T08:26	72	41	
					5	96	2012-11-03T08:26	96	0	(<20)
		3	C	2012-11-08T08:26	1	0	2012-11-08T08:16	0	0	(<20)
						0.25	2012-11-08T08:43	0.283	0	(<20)
						0.5	2012-11-08T08:58	0.533	227	
						1.5	2012-11-08T09:57	1.516	4800	
						12	2012-11-08T20:27	12.01	5230	
						2	2012-11-08T10:29	2.05	8420	
						3	2012-11-08T11:26	3	13700	

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 16 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100101	25/F/Ca	3	C	2012-11-08T08:26	1	4	2012-11-08T12:27	4.016	18100
						6	2012-11-08T14:27	6.016	11200
						8	2012-11-08T16:27	8.016	8080
					2	24	2012-11-09T08:27	24.01	1640
					3	48	2012-11-10T08:29	48.05	214
					4	72	2012-11-11T08:27	72.01	43.5
					5	96	2012-11-12T08:27	96.01	0 (<20)
MOON/100101	25/F/Ca	1	A	2012-10-30T08:20	1	0	2012-10-30T08:11	0	0 (<20)
						0.25	2012-10-30T08:35	0.25	109
						0.5	2012-10-30T08:53	0.55	2600
						1	2012-10-30T09:21	1.016	10500
						1.5	2012-10-30T09:50	1.5	15900
						2	2012-10-30T10:20	2	16200
						3	2012-10-30T11:20	3	16700
						4	2012-10-30T12:21	4.016	15600
						6	2012-10-30T14:23	6.05	13000
						8	2012-10-30T16:22	8.033	9090
					2	24	2012-10-31T08:23	24.05	2320
					3	48	2012-11-01T08:27	48.11	461
					4	72	2012-11-02T08:20	72	111

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 17 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Treatment Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100101	25/F/Ca	1	A	2012-10-30T08:20	5	96	2012-11-03T08:21	96.01	33.6
		3	C	2012-11-08T08:20	1	0	2012-11-08T08:11	0	0 (<20)
						0.25	2012-11-08T08:35	0.25	175
						1	2012-11-08T09:20	1	7830
						1.5	2012-11-08T09:50	1.5	14300
						12	2012-11-08T20:20	12	5490
						2	2012-11-08T10:22	2.033	18200
						3	2012-11-08T11:21	3.016	17600
						4	2012-11-08T12:20	4	14800
						6	2012-11-08T14:20	6	10500
						8	2012-11-08T16:21	8.016	8800
					3	48	2012-11-10T08:23	48.05	522
					4	72	2012-11-11T08:20	72	173
					5	96	2012-11-12T08:20	96	61.4
MOON/100101	25/F/Ca	1	A	2012-10-30T08:03	1	0	2012-10-30T07:53	0	0 (<20)
						0.25	2012-10-30T08:18	0.25	0 (<20)
						0.5	2012-10-30T08:34	0.516	0 (<20)
						1	2012-10-30T09:03	1	1850
						1.5	2012-10-30T09:33	1.5	9340
						12	2012-10-30T20:03	12	4190

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 18 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)	
MOON/100101	25/F/Ca	1	A	2012-10-30T08:03	1	2	2012-10-30T10:04	2.016	15200	
						3	2012-10-30T11:03	3	15700	
						4	2012-10-30T12:03	4	13300	
						6	2012-10-30T14:03	6	8570	
						8	2012-10-30T16:03	8	6900	
					2	24	2012-10-31T08:03	24	1560	
					3	48	2012-11-01T08:03	48	291	
					4	72	2012-11-02T08:03	72	61	
					5	96	2012-11-03T08:03	96	0	(<20)
		3	C	2012-11-08T08:04	1	0	2012-11-08T07:53	0	0	(<20)
						0.25	2012-11-08T08:18	0.233	0	(<20)
						0.5	2012-11-08T08:33	0.483	802	
						1	2012-11-08T09:04	1	6770	
						1.5	2012-11-08T09:34	1.5	10500	
						12	2012-11-08T20:03	11.98	4350	
						2	2012-11-08T10:04	2	13000	
						3	2012-11-08T11:03	2.983	14100	
						4	2012-11-08T12:04	4	13700	
						6	2012-11-08T14:03	5.983	9920	
						8	2012-11-08T16:04	8	7410	
					2	24	2012-11-09T08:04	24	1660	

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 19 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)	
MOON/100101	25/F/Ca	3	C	2012-11-08T08:04	3	48	2012-11-10T08:04	48	304	
					4	72	2012-11-11T08:03	71.98	70.3	
					5	96	2012-11-12T08:04	96	20.3	
MOON/100101	25/F/Ca	1	A	2012-10-30T08:27	1	0	2012-10-30T08:18	0	0	(<20)
						0.25	2012-10-30T08:42	0.25	97	
						0.5	2012-10-30T08:57	0.5	1090	
						1	2012-10-30T09:27	1	5080	
						1.5	2012-10-30T09:57	1.5	10500	
						12	2012-10-30T20:27	12	4540	
						2	2012-10-30T10:27	2	13000	
						3	2012-10-30T11:28	3.016	14400	
						4	2012-10-30T12:28	4.016	12300	
						6	2012-10-30T14:27	6	8280	
						8	2012-10-30T16:27	8	7190	
					2	24	2012-10-31T08:28	24.01	1550	
					3	48	2012-11-01T08:27	48	273	
					4	72	2012-11-02T08:27	72	53.3	
					5	96	2012-11-03T08:27	96	0	(<20)
		3	C	2012-11-08T08:27	1	0	2012-11-08T08:17	0	0	(<20)
						0.25	2012-11-08T08:44	0.283	88.5	

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 20 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Treatment Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)	
MOON/100101	25/F/Ca	3	C	2012-11-08T08:27	1	0.5	2012-11-08T08:59	0.533	3190	
						1	2012-11-08T09:28	1.016	12300	
						1.5	2012-11-08T09:57	1.5	16700	
						12	2012-11-08T20:28	12.01	3580	
						2	2012-11-08T10:28	2.016	15000	
						3	2012-11-08T11:27	3	12200	
						4	2012-11-08T12:27	4	9880	
						6	2012-11-08T14:27	6	7870	
						8	2012-11-08T16:28	8.016	5530	
					2	24	2012-11-09T08:28	24.01	1330	
					3	48	2012-11-10T08:27	48	180	
					4	72	2012-11-11T08:26	71.98	39	
					5	96	2012-11-12T08:27	96	0	(<20)
MOON/100101	25/F/Ca	1	A	2012-10-30T08:01	1	0	2012-10-30T07:51	0	0	(<20)
						0.25	2012-10-30T08:16	0.25	0	(<20)
						0.5	2012-10-30T08:31	0.5	520	
						1	2012-10-30T09:01	1	5540	
						1.5	2012-10-30T09:31	1.5	11200	
						12	2012-10-30T20:01	12	3420	
						2	2012-10-30T10:01	2	12800	

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 21 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100101	25/F/Ca	1	A	2012-10-30T08:01	1	3	2012-10-30T11:01	3	16300
						4	2012-10-30T12:01	4	13600
						6	2012-10-30T14:01	6	9130
						8	2012-10-30T16:01	8	6050
					2	24	2012-10-31T08:01	24	984
					3	48	2012-11-01T08:01	48	130
					4	72	2012-11-02T08:01	72	23.4
					5	96	2012-11-03T08:01	96	0 (<20)
		3	C	2012-11-08T08:01	1	0	2012-11-08T07:51	0	0 (<20)
						0.25	2012-11-08T08:16	0.25	83.1
						0.5	2012-11-08T08:28	0.45	2420
						1	2012-11-08T09:02	1.016	11600
						1.5	2012-11-08T09:31	1.5	14800
						12	2012-11-08T20:01	12	3700
						2	2012-11-08T10:02	2.016	15000
						3	2012-11-08T11:01	3	14300
						4	2012-11-08T12:01	4	12500
						6	2012-11-08T14:01	6	7770
						8	2012-11-08T16:01	8	6060
					2	24	2012-11-09T08:01	24	1060
					3	48	2012-11-10T08:01	48	118

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 22 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Treatment Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)	
MOON/100101	25/F/Ca	3	C	2012-11-08T08:01	4	72	2012-11-11T08:01	72	0	(<20)
					5	96	2012-11-12T08:01	96	0	(<20)
MOON/100101	25/F/Ca	1	A	2012-10-30T08:17	1	0	2012-10-30T08:07	0	0	(<20)
						0.25	2012-10-30T08:33	0.266	367	
						0.5	2012-10-30T08:47	0.5	3000	
						1	2012-10-30T09:17	1	12800	
						1.5	2012-10-30T09:47	1.5	16300	
						12	2012-10-30T20:17	12	2440	
						2	2012-10-30T10:17	2	14200	
						3	2012-10-30T11:17	3	12300	
						4	2012-10-30T12:17	4	10700	
						6	2012-10-30T14:18	6.016	6300	
						8	2012-10-30T16:17	8	4490	
					2	24	2012-10-31T08:17	24	805	
					3	48	2012-11-01T08:17	48	109	
					4	72	2012-11-02T08:17	72	0	(<20)
					5	96	2012-11-03T08:18	96.01	0	(<20)
		3	C	2012-11-08T08:17	1	0	2012-11-08T08:07	0	0	(<20)
						0.25	2012-11-08T08:32	0.25	425	
						0.5	2012-11-08T08:47	0.5	3700	

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 23 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100101	25/F/Ca	3	C	2012-11-08T08:17	1	1	2012-11-08T09:18	1.016	12900
						1.5	2012-11-08T09:47	1.5	17100
						12	2012-11-08T20:17	12	3150
						2	2012-11-08T10:17	2	17100
						3	2012-11-08T11:17	3	14200
						4	2012-11-08T12:17	4	11400
						6	2012-11-08T14:17	6	7370
						8	2012-11-08T16:17	8	5700
					2	24	2012-11-09T08:17	24	1070
					3	48	2012-11-10T08:17	48	121
					4	72	2012-11-11T08:17	72	23.3
					5	96	2012-11-12T08:17	96	0 (<20)
MOON/100101	25/F/Ca	1	A	2012-10-30T08:13	1	0	2012-10-30T08:03	0	0 (<20)
						0.25	2012-10-30T08:28	0.25	46.9
						0.5	2012-10-30T08:43	0.5	774
						1	2012-10-30T09:13	1	3980
						1.5	2012-10-30T09:43	1.5	6030
						12	2012-10-30T20:13	12	5480
						2	2012-10-30T10:13	2	8500
						3	2012-10-30T11:13	3	24900

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 24 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Treatment Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100101	25/F/Ca	1	A	2012-10-30T08:13	1	4	2012-10-30T12:13	4	22900
						6	2012-10-30T14:13	6	15200
						8	2012-10-30T16:13	8	10500
					2	24	2012-10-31T08:13	24	1890
					3	48	2012-11-01T08:13	48	288
					4	72	2012-11-02T08:13	72	52.7
					5	96	2012-11-03T08:13	96	0 (<20)
		3	C	2012-11-08T08:13	1	0	2012-11-08T08:03	0	0 (<20)
						0.25	2012-11-08T08:28	0.25	0 (<20)
						0.5	2012-11-08T08:43	0.5	411
						1	2012-11-08T09:13	1	2500
						1.5	2012-11-08T09:43	1.5	6180
						12	2012-11-08T20:13	12	5390
						2	2012-11-08T10:13	2	9530
						3	2012-11-08T11:13	3	20600
						4	2012-11-08T12:13	4	22500
						6	2012-11-08T14:13	6	13800
						8	2012-11-08T16:14	8.016	9640
					2	24	2012-11-09T08:13	24	1790
					3	48	2012-11-10T08:13	48	303
					4	72	2012-11-11T08:13	72	57.2

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 25 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Treatment Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100101	25/F/Ca	3	C	2012-11-08T08:13	5	96	2012-11-12T08:13	96	22.9
MOON/100101	25/F/Ca	1	A	2012-10-30T08:05	1	0	2012-10-30T07:55	0	0 (<20)
						0.25	2012-10-30T08:20	0.25	105
						0.5	2012-10-30T08:35	0.5	3100
						1	2012-10-30T09:05	1	14300
						1.5	2012-10-30T09:35	1.5	19300
						12	2012-10-30T20:05	12	5130
						2	2012-10-30T10:06	2.016	22500
						3	2012-10-30T11:05	3	14700
						4	2012-10-30T12:05	4	14300
						6	2012-10-30T14:05	6	11500
						8	2012-10-30T16:05	8	7940
					2	24	2012-10-31T08:05	24	2020
					3	48	2012-11-01T08:05	48	314
					4	72	2012-11-02T08:05	72	70.3
					5	96	2012-11-03T08:05	96	0 (<20)
		3	C	2012-11-08T08:06	1	0	2012-11-08T07:55	0	0 (<20)
						0.25	2012-11-08T08:20	0.233	0 (<20)
						0.5	2012-11-08T08:36	0.5	626
						1	2012-11-08T09:06	1	8150

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 26 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Treatment Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100101	25/F/Ca	3	C	2012-11-08T08:06	1	1.5	2012-11-08T09:36	1.5	17500
						12	2012-11-08T20:06	12	5800
						2	2012-11-08T10:06	2	21800
						3	2012-11-08T11:06	3	22600
						4	2012-11-08T12:06	4	17900
						6	2012-11-08T14:05	5.983	11800
						8	2012-11-08T16:06	8	8770
					2	24	2012-11-09T08:06	24	2310
					3	48	2012-11-10T08:06	48	374
					4	72	2012-11-11T08:05	71.98	79.6
					5	96	2012-11-12T08:06	96	26.2
MOON/100101	25/F/Ca	1	A	2012-10-30T08:06	1	0	2012-10-30T07:56	0	0 (<20)
						0.25	2012-10-30T08:21	0.25	65.9
						0.5	2012-10-30T08:37	0.516	1600
						1	2012-10-30T09:06	1	12200
						1.5	2012-10-30T09:36	1.5	19400
						12	2012-10-30T20:06	12	3870
						2	2012-10-30T10:06	2	19500
						3	2012-10-30T11:06	3	17400
						4	2012-10-30T12:06	4	13600

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 27 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)	
MOON/100101	25/F/Ca	1	A	2012-10-30T08:06	1	6	2012-10-30T14:06	6	8340	
						8	2012-10-30T16:06	8	5620	
					2	24	2012-10-31T08:06	24	1370	
					3	48	2012-11-01T08:06	48	221	
					4	72	2012-11-02T08:06	72	47.8	
					5	96	2012-11-03T08:06	96	0	(<20)
		3	C	2012-11-08T08:06	1	0	2012-11-08T07:56	0	0	(<20)
						0.25	2012-11-08T08:21	0.25	38.1	
						0.5	2012-11-08T08:36	0.5	1510	
						1	2012-11-08T09:06	1	14100	
						1.5	2012-11-08T09:36	1.5	19500	
						12	2012-11-08T20:06	12	3870	
						2	2012-11-08T10:07	2.016	19300	
						3	2012-11-08T11:06	3	14700	
						4	2012-11-08T12:06	4	13600	
						6	2012-11-08T14:06	6	9140	
						8	2012-11-08T16:06	8	6660	
					2	24	2012-11-09T08:06	24	1390	
					3	48	2012-11-10T08:06	48	198	
					4	72	2012-11-11T08:06	72	53.9	
					5	96	2012-11-12T08:06	96	0	(<20)

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 28 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Treatment Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)	
MOON/100102	25/F/Ca	1	A	2012-10-30T08:19	1	0	2012-10-30T08:09	0	0	(<20)
						0.25	2012-10-30T08:34	0.25	143	
						0.5	2012-10-30T08:49	0.5	2430	
						1	2012-10-30T09:19	1	9970	
						1.5	2012-10-30T09:49	1.5	16200	
						12	2012-10-30T20:19	12	2820	
						2	2012-10-30T10:19	2	14600	
						3	2012-10-30T11:19	3	13500	
						4	2012-10-30T12:19	4	12100	
						6	2012-10-30T14:19	6	7760	
						8	2012-10-30T16:19	8	4930	
					2	24	2012-10-31T08:20	24.01	807	
					3	48	2012-11-01T08:19	48	107	
					4	72	2012-11-02T08:19	72	0	(<20)
					5	96	2012-11-03T08:20	96.01	0	(<20)
		3	C	2012-11-08T08:19	1	0	2012-11-08T08:09	0	0	(<20)
						0.25	2012-11-08T08:34	0.25	74.2	
						0.5	2012-11-08T08:49	0.5	1620	
						1	2012-11-08T09:19	1	7560	
						1.5	2012-11-08T09:49	1.5	11600	
						12	2012-11-08T20:19	12	2990	

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 29 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Treatment Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100102	25/F/Ca	3	C	2012-11-08T08:19	1	2	2012-11-08T10:19	2	11700
						3	2012-11-08T11:19	3	14700
						4	2012-11-08T12:19	4	12600
						6	2012-11-08T14:19	6	8450
						8	2012-11-08T16:19	8	5040
					2	24	2012-11-09T08:19	24	845
					3	48	2012-11-10T08:19	48	90.5
					4	72	2012-11-11T08:19	72	0 (<20)
					5	96	2012-11-12T08:19	96	0 (<20)
MOON/100102	25/F/Ca	1	A	2012-10-30T08:11	1	0	2012-10-30T08:01	0	0 (<20)
						0.25	2012-10-30T08:26	0.25	27.6
						0.5	2012-10-30T08:41	0.5	1010
						1	2012-10-30T09:11	1	8310
						1.5	2012-10-30T09:41	1.5	14500
						12	2012-10-30T20:11	12	4920
						2	2012-10-30T10:11	2	16300
						3	2012-10-30T11:11	3	15800
						4	2012-10-30T12:11	4	13300
						6	2012-10-30T14:11	6	9980
						8	2012-10-30T16:11	8	6700

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 30 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100102	25/F/Ca	1	A	2012-10-30T08:11	2	24	2012-10-31T08:11	24	2200
					3	48	2012-11-01T08:11	48	355
					4	72	2012-11-02T08:11	72	80.1
					5	96	2012-11-03T08:11	96	0 (<20)
		3	C	2012-11-08T08:12	1	0	2012-11-08T08:01	0	0 (<20)
						0.25	2012-11-08T08:27	0.25	0 (<20)
						0.5	2012-11-08T08:43	0.516	1630
						1	2012-11-08T09:12	1	11000
						1.5	2012-11-08T09:42	1.5	17100
						12	2012-11-08T20:12	12	4860
						2	2012-11-08T10:13	2.016	19200
						3	2012-11-08T11:12	3	16000
						4	2012-11-08T12:13	4.016	13000
						6	2012-11-08T14:12	6	9080
						8	2012-11-08T16:12	8	7360
					2	24	2012-11-09T08:12	24	2070
					3	48	2012-11-10T08:12	48	379
					4	72	2012-11-11T08:12	72	112
					5	96	2012-11-12T08:12	96	39.9
MOON/100102	25/F/Ca	1	A	2012-10-30T08:09	1	0	2012-10-30T07:59	0	0 (<20)

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 31 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100102	25/F/Ca	1	A	2012-10-30T08:09	1	0.25	2012-10-30T08:24	0.25	63.1
						0.5	2012-10-30T08:39	0.5	2670
						1	2012-10-30T09:09	1	14900
						1.5	2012-10-30T09:39	1.5	24400
						12	2012-10-30T20:09	12	7980
						2	2012-10-30T10:09	2	23400
						3	2012-10-30T11:09	3	24100
						4	2012-10-30T12:09	4	18500
						6	2012-10-30T14:09	6	14300
						8	2012-10-30T16:09	8	11500
					2	24	2012-10-31T08:09	24	4020
					3	48	2012-11-01T08:09	48	928
					4	72	2012-11-02T08:09	72	247
					5	96	2012-11-03T08:09	96	84.1
		3	C	2012-11-08T08:09	1	0	2012-11-08T07:59	0	0 (<20)
						0.25	2012-11-08T08:25	0.266	82
						0.5	2012-11-08T08:40	0.516	1530
						1	2012-11-08T09:09	1	10700
						1.5	2012-11-08T09:39	1.5	18600
						12	2012-11-08T20:09	12	6770
						2	2012-11-08T10:09	2	21000

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 32 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Treatment Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100102	25/F/Ca	3	C	2012-11-08T08:09	1	3	2012-11-08T11:09	3	21400
						4	2012-11-08T12:09	4	17000
						6	2012-11-08T14:09	6	13200
						8	2012-11-08T16:09	8	10400
					2	24	2012-11-09T08:09	24	3300
					3	48	2012-11-10T08:09	48	762
					4	72	2012-11-11T08:09	72	216
					5	96	2012-11-12T08:09	96	86.9
MOON/100102	25/F/Ca	1	A	2012-10-30T08:00	1	0	2012-10-30T07:50	0	0 (<20)
						0.25	2012-10-30T08:15	0.25	0 (<20)
						0.5	2012-10-30T08:30	0.5	368
						1	2012-10-30T09:00	1	2010
						1.5	2012-10-30T09:30	1.5	4790
						12	2012-10-30T20:00	12	3360
						2	2012-10-30T10:00	2	7060
						3	2012-10-30T11:00	3	9060
						4	2012-10-30T12:02	4.033	15400
						6	2012-10-30T14:00	6	9570
						8	2012-10-30T16:00	8	6200
					2	24	2012-10-31T08:00	24	866

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 33 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100102	25/F/Ca	1	A	2012-10-30T08:00	3	48	2012-11-01T08:00	48	83.2
					4	72	2012-11-02T08:00	72	0 (<20)
					5	96	2012-11-03T08:00	96	0 (<20)
		3	C	2012-11-08T08:00	1	0	2012-11-08T07:50	0	0 (<20)
						0.25	2012-11-08T08:15	0.25	25.1
						0.5	2012-11-08T08:30	0.5	1250
						1	2012-11-08T09:02	1.033	9950
						1.5	2012-11-08T09:30	1.5	13200
						12	2012-11-08T20:00	12	2820
						2	2012-11-08T10:01	2.016	13600
						3	2012-11-08T11:00	3	14300
						4	2012-11-08T12:00	4	11100
						6	2012-11-08T14:00	6	7440
						8	2012-11-08T16:00	8	5110
					2	24	2012-11-09T08:00	24	871
					3	48	2012-11-10T08:00	48	69.1
					4	72	2012-11-11T08:00	72	0 (<20)
					5	96	2012-11-12T08:00	96	0 (<20)
MOON/100102	25/F/Ca	1	A	2012-10-30T08:22	1	0	2012-10-30T08:13	0	0 (<20)
						0.25	2012-10-30T08:37	0.25	419

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 34 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100102	25/F/Ca	1	A	2012-10-30T08:22	1	0.5	2012-10-30T08:52	0.5	5700
						1	2012-10-30T09:22	1	17900
						1.5	2012-10-30T09:52	1.5	19500
						12	2012-10-30T20:22	12	4220
						2	2012-10-30T10:23	2.016	17800
						3	2012-10-30T11:22	3	15100
						4	2012-10-30T12:22	4	12800
						6	2012-10-30T14:23	6.016	8450
						8	2012-10-30T16:22	8	6730
					2	24	2012-10-31T08:25	24.05	1420
					3	48	2012-11-01T08:24	48.03	197
					4	72	2012-11-02T08:22	72	51.6
					5	96	2012-11-03T08:22	96	0 (<20)
		3	C	2012-11-08T08:22	1	0	2012-11-08T08:12	0	0 (<20)
						0.25	2012-11-08T08:37	0.25	0 (<20)
						0.5	2012-11-08T08:54	0.533	562
						1	2012-11-08T09:22	1	4590
						1.5	2012-11-08T09:52	1.5	9280
						12	2012-11-08T20:22	12	5560
						2	2012-11-08T10:23	2.016	13200
						3	2012-11-08T11:22	3	18400

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 35 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Treatment Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100102	25/F/Ca	3	C	2012-11-08T08:22	1	4	2012-11-08T12:23	4.016	17900
						6	2012-11-08T14:22	6	11200
						8	2012-11-08T16:22	8	9020
					2	24	2012-11-09T08:23	24.01	2150
					3	48	2012-11-10T08:23	48.01	318
					4	72	2012-11-11T08:22	72	97.6
					5	96	2012-11-12T08:23	96.01	40.7
MOON/100102	25/F/Ca	1	A	2012-10-30T08:07	1	0	2012-10-30T07:57	0	0 (<20)
						0.25	2012-10-30T08:22	0.25	38.6
						0.5	2012-10-30T08:37	0.5	1380
						1	2012-10-30T09:07	1	5890
						1.5	2012-10-30T09:37	1.5	10200
						12	2012-10-30T20:07	12	4540
						2	2012-10-30T10:08	2.016	12300
						3	2012-10-30T11:07	3	14800
						4	2012-10-30T12:07	4	15400
						6	2012-10-30T14:07	6	12800
						8	2012-10-30T16:07	8	9550
					2	24	2012-10-31T08:07	24	2900
					3	48	2012-11-01T08:07	48	597

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 36 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100102	25/F/Ca	1	A	2012-10-30T08:07	4	72	2012-11-02T08:07	72	115
					5	96	2012-11-03T08:07	96	34.4
		3	C	2012-11-08T08:07	1	0	2012-11-08T07:57	0	0 (<20)
						0.25	2012-11-08T08:23	0.266	358
						0.5	2012-11-08T08:39	0.533	3400
						1	2012-11-08T09:07	1	14600
						1.5	2012-11-08T09:37	1.5	19900
						12	2012-11-08T20:08	12.01	4960
						2	2012-11-08T10:08	2.016	21200
						3	2012-11-08T11:07	3	15700
						4	2012-11-08T12:07	4	17400
						6	2012-11-08T14:07	6	12100
						8	2012-11-08T16:09	8.033	9050
					2	24	2012-11-09T08:08	24.01	2780
					3	48	2012-11-10T08:07	48	562
					4	72	2012-11-11T08:07	72	163
					5	96	2012-11-12T08:07	96	68.1
MOON/100102	25/F/Ca	1	A	2012-10-30T08:16	1	0	2012-10-30T08:06	0	0 (<20)
						0.25	2012-10-30T08:32	0.266	26.4
						0.5	2012-10-30T08:46	0.5	654

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 37 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Treatment Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)	
MOON/100102	25/F/Ca	1	A	2012-10-30T08:16	1	1	2012-10-30T09:16	1	5700	
						1.5	2012-10-30T09:46	1.5	9720	
						12	2012-10-30T20:16	12	3670	
						2	2012-10-30T10:16	2	12900	
						3	2012-10-30T11:16	3	13600	
						4	2012-10-30T12:17	4.016	15100	
						6	2012-10-30T14:16	6	9290	
						8	2012-10-30T16:16	8	6270	
					2	24	2012-10-31T08:16	24	1200	
					3	48	2012-11-01T08:16	48	117	
					4	72	2012-11-02T08:16	72	20	
					5	96	2012-11-03T08:16	96	0	(<20)
		3	C	2012-11-08T08:16	1	0	2012-11-08T08:06	0	0	(<20)
						0.25	2012-11-08T08:31	0.25	0	(<20)
						0.5	2012-11-08T08:46	0.5	609	
						1	2012-11-08T09:16	1	9150	
						1.5	2012-11-08T09:46	1.5	14300	
						12	2012-11-08T20:16	12	3460	
						2	2012-11-08T10:16	2	15400	
						3	2012-11-08T11:16	3	14700	
						4	2012-11-08T12:16	4	12400	

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 38 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Treatment Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)	
MOON/100102	25/F/Ca	3	C	2012-11-08T08:16	1	6	2012-11-08T14:16	6	7540	
						8	2012-11-08T16:16	8	6020	
					2	24	2012-11-09T08:16	24	1010	
					3	48	2012-11-10T08:16	48	119	
					4	72	2012-11-11T08:16	72	0	(<20)
					5	96	2012-11-12T08:16	96	0	(<20)
MOON/100102	25/F/Ca	1	A	2012-10-30T08:02	1	0	2012-10-30T07:52	0	0	(<20)
						0.25	2012-10-30T08:17	0.25	0	(<20)
						0.5	2012-10-30T08:32	0.5	407	
						1	2012-10-30T09:02	1	4770	
						1.5	2012-10-30T09:32	1.5	8500	
						12	2012-10-30T20:02	12	4730	
						2	2012-10-30T10:02	2	10200	
						3	2012-10-30T11:02	3	10200	
						4	2012-10-30T12:02	4	12900	
						6	2012-10-30T14:02	6	10600	
						8	2012-10-30T16:02	8	8230	
					2	24	2012-10-31T08:03	24.01	1650	
					3	48	2012-11-01T08:02	48	253	
					4	72	2012-11-02T08:02	72	53.8	

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 39 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100102	25/F/Ca	1	A	2012-10-30T08:02	5	96	2012-11-03T08:02	96	0 (<20)
		3	C	2012-11-08T08:02	1	0	2012-11-08T07:52	0	0 (<20)
						0.25	2012-11-08T08:17	0.25	63.2
						0.5	2012-11-08T08:32	0.5	2050
						1	2012-11-08T09:03	1.016	15700
						1.5	2012-11-08T09:33	1.516	23700
						12	2012-11-08T20:02	12	4040
						2	2012-11-08T10:04	2.033	20800
						3	2012-11-08T11:02	3	14700
						4	2012-11-08T12:02	4	11900
						6	2012-11-08T14:02	6	8670
						8	2012-11-08T16:03	8.016	6360
					2	24	2012-11-09T08:04	24.03	1550
					3	48	2012-11-10T08:03	48.01	204
					4	72	2012-11-11T08:02	72	46.7
					5	96	2012-11-12T08:02	96	0 (<20)
MOON/100102	25/F/Ca	1	A	2012-10-30T08:21	1	0	2012-10-30T08:13	0	0 (<20)
						0.25	2012-10-30T08:36	0.25	147
						0.5	2012-10-30T08:51	0.5	3120
						1	2012-10-30T09:21	1	14800

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 40 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100102	25/F/Ca	1	A	2012-10-30T08:21	1	1.5	2012-10-30T09:51	1.5	18700
						12	2012-10-30T20:21	12	6380
						2	2012-10-30T10:22	2.016	17700
						3	2012-10-30T11:21	3	16100
						4	2012-10-30T12:21	4	13900
						6	2012-10-30T14:22	6.016	10900
						8	2012-10-30T16:21	8	8250
					2	24	2012-10-31T08:23	24.03	3000
					3	48	2012-11-01T08:23	48.03	763
					4	72	2012-11-02T08:21	72	216
					5	96	2012-11-03T08:21	96	66.4
		3	C	2012-11-08T08:21	1	0	2012-11-08T08:11	0	0 (<20)
						0.25	2012-11-08T08:36	0.25	23.9
						0.5	2012-11-08T08:53	0.533	1250
						1	2012-11-08T09:21	1	11400
						1.5	2012-11-08T09:51	1.5	16800
						12	2012-11-08T20:21	12	6230
						2	2012-11-08T10:21	2	16400
						3	2012-11-08T11:21	3	17000
						4	2012-11-08T12:22	4.016	14400
						6	2012-11-08T14:21	6	10500

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PCL (Page 41 of 41)
Individual pharmacokinetic concentrations
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment Sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Treatment Period	Treatment Name	Treatment Date/Time of dosing	Profile day	Scheduled Sampling Time (h)	Date/Time of collection	Elapsed Time (h)	Concentration (ng/mL)
MOON/100102	25/F/Ca	3	C	2012-11-08T08:21	1	8	2012-11-08T16:22	8.016	6150
					2	24	2012-11-09T08:22	24.01	2910
					3	48	2012-11-10T08:21	48	697
					4	72	2012-11-11T08:21	72	210
					5	96	2012-11-12T08:22	96.01	71.6

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was collected.
Value * was not considered for summary and inferential procedures.
Value + was excluded from estimation of PK parameters.
For values <LLOQ, the reported (<LLOQ) values are presented.
Data: adpc Program: pcl.sas Output: l.16.2.5.pcl.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Listing 16.2.5-PPLh (Page 1 of 8)
Individual pharmacokinetic parameters
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL 2
Treatment sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Treatment Period	Treatment Name	Profile day	AUC (h*ng/mL)	AUC(0-tlast) (h*ng/mL)	CL/F (mL/h)	Cmax (ng/mL)
MOON/1001001	25/F/Ca	1	A	1	299000	298000	1340	26400
		3	C	1	252000	251000	1590	19700
MOON/1001002	25/F/Ca	1	A	1	113000	112000	3550	7920
		3	C	1	127000	127000	3140	11500
MOON/1001003	25/F/Ca	1	A	1	138000	138000	2890	16200
		3	C	1	165000	164000	2430	21700
MOON/1001004	25/F/Ca	1	A	1	190000	190000	2100	17600
MOON/1001005	25/F/Ca	1	A	1	146000	146000	2730	17800
		3	C	1	145000	145000	2750	19100
MOON/1001006	25/F/Ca	1	A	1	184000	183000	2170	16100
		3	C	1	188000	188000	2120	16300
MOON/1001007	25/F/Ca	1	A	1	120000	120000	3330	14400
		3	C	1	130000	129000	3080	16300
MOON/1001008	25/F/Ca	1	A	1	195000	194000	2060	18000
		3	C	1	186000	185000	2150	18700

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was calculated.
Value * was not considered for summary and inferential procedures.
Data: adpp Program: ppl.sas Output: l.16.2.5.pplh.txt
Fake Data/ Production Run on 11MAR2014:10:32

Listing 16.2.5-PPLh (Page 2 of 8)
Individual pharmacokinetic parameters
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL 2
Treatment sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Profile day	t1/2 (h)	tmax (h)
MOON/1001001	25/F/Ca	1	A	1	12.9	2.00
		3	C	1	12.8	4.03
MOON/1001002	25/F/Ca	1	A	1	9.92	4.00
		3	C	1	9.41	3.00
MOON/1001003	25/F/Ca	1	A	1	8.89	2.00
		3	C	1	8.22	2.00
MOON/1001004	25/F/Ca	1	A	1	9.05	1.50
MOON/1001005	25/F/Ca	1	A	1	6.66	2.02
		3	C	1	9.36	1.50
MOON/1001006	25/F/Ca	1	A	1	12.1	3.02
		3	C	1	12.1	2.98
MOON/1001007	25/F/Ca	1	A	1	8.99	3.05
		3	C	1	9.89	1.50
MOON/1001008	25/F/Ca	1	A	1	11.9	1.50
		3	C	1	15.5	2.00

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was calculated.
Value * was not considered for summary and inferential procedures.
Data: adpp Program: ppl.sas Output: l.16.2.5.pplh.txt
Fake Data/ Production Run on 11MAR2014:10:32

Study001

Listing 16.2.5-PPLh (Page 3 of 8)
Individual pharmacokinetic parameters
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL 2
Treatment sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Treatment Period	Treatment Name	Profile day	AUC (h*ng/mL)	AUC(0-tlast) (h*ng/mL)	CL/F (mL/h)	Cmax (ng/mL)
MOON/1001009	25/F/Ca	1	A	1	191000	191000	2090	22300
		3	C	1	180000	179000	2230	17800
MOON/1001010	25/F/Ca	1	A	1	174000	174000	2290	17500
		3	C	1	192000	192000	2080	17500
MOON/1001011	25/F/Ca	1	A	1	157000	157000	2540	18200
		3	C	1	175000	174000	2280	18100
MOON/1001012	25/F/Ca	1	A	1	236000	235000	1700	16700
		3	C	1	245000	243000	1640	18200
MOON/1001013	25/F/Ca	1	A	1	161000	160000	2490	15700
		3	C	1	170000	169000	2360	14100
MOON/1001014	25/F/Ca	1	A	1	161000	160000	2480	14400
		3	C	1	144000	143000	2780	16700
MOON/1001015	25/F/Ca	1	A	1	140000	140000	2860	16300
		3	C	1	144000	142000	2780	15000
MOON/1001016	25/F/Ca	1	A	1	117000	116000	3410	16300
		3	C	1	140000	140000	2850	17100

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was calculated.
Value * was not considered for summary and inferential procedures.
Data: adpp Program: ppl.sas Output: l.16.2.5.pplh.txt
Fake Data/ Production Run on 11MAR2014:10:32

Listing 16.2.5-PPLh (Page 4 of 8)
Individual pharmacokinetic parameters
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL 2
Treatment sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Profile day	t1/2 (h)	tmax (h)
MOON/1001009	25/F/Ca	1	A	1	11.5	1.50
		3	C	1	12.5	2.00
MOON/1001010	25/F/Ca	1	A	1	9.37	1.50
		3	C	1	11.2	1.52
MOON/1001011	25/F/Ca	1	A	1	9.32	1.50
		3	C	1	9.17	4.02
MOON/1001012	25/F/Ca	1	A	1	11.8	3.00
		3	C	1	13.0	2.03
MOON/1001013	25/F/Ca	1	A	1	9.90	3.00
		3	C	1	11.3	2.98
MOON/1001014	25/F/Ca	1	A	1	9.44	3.02
		3	C	1	9.13	1.50
MOON/1001015	25/F/Ca	1	A	1	8.40	3.00
		3	C	1	7.29	2.02
MOON/1001016	25/F/Ca	1	A	1	7.66	1.50
		3	C	1	8.69	1.50

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was calculated.
Value * was not considered for summary and inferential procedures.
Data: adpp Program: ppl.sas Output: l.16.2.5.pplh.txt
Fake Data/ Production Run on 11MAR2014:10:32

Listing 16.2.5-PPLh (Page 5 of 8)
Individual pharmacokinetic parameters
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL 2
Treatment sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Profile day	AUC (h*ng/mL)	AUC(0-tlast) (h*ng/mL)	CL/F (mL/h)	Cmax (ng/mL)
MOON/1001017	25/F/Ca	1	A	1	219000	218000	1830	24900
		3	C	1	207000	207000	1930	22500
MOON/1001018	25/F/Ca	1	A	1	205000	204000	1950	22500
		3	C	1	228000	228000	1750	22600
MOON/1001019	25/F/Ca	1	A	1	164000	164000	2430	19500
		3	C	1	167000	167000	2390	19500
MOON/1001020	25/F/Ca	1	A	1	126000	125000	3160	16200
		3	C	1	126000	125000	3180	14700
MOON/1001021	25/F/Ca	1	A	1	189000	188000	2110	16300
		3	C	1	194000	193000	2060	19200
MOON/1001022	25/F/Ca	1	A	1	320000	319000	1250	24400
		3	C	1	275000	273000	1450	21400
MOON/1001023	25/F/Ca	1	A	1	123000	122000	3250	15400
		3	C	1	123000	122000	3250	14300
MOON/1001024	25/F/Ca	1	A	1	171000	171000	2340	19500
		3	C	1	206000	205000	1940	18400

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was calculated.
Value * was not considered for summary and inferential procedures.
Data: adpp Program: ppl.sas Output: l.16.2.5.pplh.txt
Fake Data/ Production Run on 11MAR2014:10:32

Listing 16.2.5-PPLh (Page 6 of 8)
Individual pharmacokinetic parameters
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL 2
Treatment sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Profile day	t1/2 (h)	tmax (h)
MOON/1001017	25/F/Ca	1	A	1	8.99	3.00
		3	C	1	11.3	4.00
MOON/1001018	25/F/Ca	1	A	1	9.64	2.02
		3	C	1	11.1	3.00
MOON/1001019	25/F/Ca	1	A	1	9.49	2.00
		3	C	1	10.2	1.50
MOON/1001020	25/F/Ca	1	A	1	7.37	1.50
		3	C	1	7.18	3.00
MOON/1001021	25/F/Ca	1	A	1	9.98	2.00
		3	C	1	12.7	2.02
MOON/1001022	25/F/Ca	1	A	1	12.9	1.50
		3	C	1	13.7	3.00
MOON/1001023	25/F/Ca	1	A	1	6.80	4.03
		3	C	1	6.70	3.00
MOON/1001024	25/F/Ca	1	A	1	9.40	1.50
		3	C	1	12.7	3.00

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was calculated.
Value * was not considered for summary and inferential procedures.
Data: adpp Program: ppl.sas Output: l.16.2.5.pplh.txt
Fake Data/ Production Run on 11MAR2014:10:32

Listing 16.2.5-PPLh (Page 7 of 8)
Individual pharmacokinetic parameters
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL 2
Treatment sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Profile day	AUC (h*ng/mL)	AUC(0-tlast) (h*ng/mL)	CL/F (mL/h)	Cmax (ng/mL)
MOON/1001025	25/F/Ca	1	A	1	216000	216000	1850	15400
		3	C	1	237000	236000	1690	21200
MOON/1001026	25/F/Ca	1	A	1	146000	145000	2750	15100
		3	C	1	139000	137000	2890	15400
MOON/1001027	25/F/Ca	1	A	1	165000	164000	2430	12900
		3	C	1	171000	171000	2330	23700
MOON/1001028	25/F/Ca	1	A	1	246000	244000	1630	18700
		3	C	1	231000	230000	1730	17000

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was calculated.
Value * was not considered for summary and inferential procedures.
Data: adpp Program: ppl.sas Output: l.16.2.5.pplh.txt
Fake Data/ Production Run on 11MAR2014:10:32

Listing 16.2.5-PPLh (Page 8 of 8)
Individual pharmacokinetic parameters
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL 2
Treatment sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Profile day	t1/2 (h)	tmax (h)
MOON/1001025	25/F/Ca	1	A	1	11.1	4.00
		3	C	1	13.5	2.02
MOON/1001026	25/F/Ca	1	A	1	7.90	4.02
		3	C	1	7.46	2.00
MOON/1001027	25/F/Ca	1	A	1	9.30	4.00
		3	C	1	9.49	1.52
MOON/1001028	25/F/Ca	1	A	1	13.1	1.50
		3	C	1	13.5	3.00

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was calculated.
Value * was not considered for summary and inferential procedures.
Data: adpp Program: ppl.sas Output: l.16.2.5.pplh.txt
Fake Data/ Production Run on 11MAR2014:10:32

Study001

Listing 16.2.5-PPLv (Page 1 of 16)
Individual pharmacokinetic parameters
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL 2
Treatment sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Profile day	Parameter	Value
MOON/1001001	25/F/Ca	1	A	1	AUC (h*ng/mL)	299000
					AUC(0-tlast)(h*ng/mL)	298000
					CL/F (mL/h)	1340
					Cmax (ng/mL)	26400
					t1/2 (h)	12.9
					tmax (h)	2.00
		3	C	1	AUC (h*ng/mL)	252000
					AUC(0-tlast)(h*ng/mL)	251000
					CL/F (mL/h)	1590
					Cmax (ng/mL)	19700
					t1/2 (h)	12.8
					tmax (h)	4.03
MOON/1001002	25/F/Ca	1	A	1	AUC (h*ng/mL)	113000
					AUC(0-tlast)(h*ng/mL)	112000
					CL/F (mL/h)	3550
					Cmax (ng/mL)	7920
					t1/2 (h)	9.92
					tmax (h)	4.00
		3	C	1	AUC (h*ng/mL)	127000
					AUC(0-tlast)(h*ng/mL)	127000
					CL/F (mL/h)	3140

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was calculated.
Value * was not considered for summary and inferential procedures.
Data: adpp Program: ppl.sas Output: l.16.2.5.pplv.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PPLv (Page 2 of 16)
Individual pharmacokinetic parameters
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL 2
Treatment sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Profile day	Parameter	Value
MOON/1001002	25/F/Ca	3	C	1	Cmax (ng/mL)	11500
					t1/2 (h)	9.41
					tmax (h)	3.00
MOON/1001003	25/F/Ca	1	A	1	AUC (h*ng/mL)	138000
					AUC(0-tlast)(h*ng/mL)	138000
					CL/F (mL/h)	2890
					Cmax (ng/mL)	16200
					t1/2 (h)	8.89
					tmax (h)	2.00
		3	C	1	AUC (h*ng/mL)	165000
					AUC(0-tlast)(h*ng/mL)	164000
					CL/F (mL/h)	2430
					Cmax (ng/mL)	21700
					t1/2 (h)	8.22
					tmax (h)	2.00
MOON/1001004	25/F/Ca	1	A	1	AUC (h*ng/mL)	190000
					AUC(0-tlast)(h*ng/mL)	190000
					CL/F (mL/h)	2100
					Cmax (ng/mL)	17600
					t1/2 (h)	9.05
					tmax (h)	1.50

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was calculated.
Value * was not considered for summary and inferential procedures.
Data: adpp Program: ppl.sas Output: l.16.2.5.pplv.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PPLv (Page 3 of 16)
Individual pharmacokinetic parameters
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL 2
Treatment sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Profile day	Parameter	Value
MOON/1001005	25/F/Ca	1	A	1	AUC (h*ng/mL)	146000
					AUC(0-tlast)(h*ng/mL)	146000
					CL/F (mL/h)	2730
					Cmax (ng/mL)	17800
					t1/2 (h)	6.66
					tmax (h)	2.02
		3	C	1	AUC (h*ng/mL)	145000
					AUC(0-tlast)(h*ng/mL)	145000
					CL/F (mL/h)	2750
					Cmax (ng/mL)	19100
					t1/2 (h)	9.36
					tmax (h)	1.50
MOON/1001006	25/F/Ca	1	A	1	AUC (h*ng/mL)	184000
					AUC(0-tlast)(h*ng/mL)	183000
					CL/F (mL/h)	2170
					Cmax (ng/mL)	16100
					t1/2 (h)	12.1
					tmax (h)	3.02
		3	C	1	AUC (h*ng/mL)	188000
					AUC(0-tlast)(h*ng/mL)	188000
					CL/F (mL/h)	2120

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was calculated.
Value * was not considered for summary and inferential procedures.
Data: adpp Program: ppl.sas Output: l.16.2.5.pplv.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PPLv (Page 4 of 16)
Individual pharmacokinetic parameters
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL 2
Treatment sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Profile day	Parameter	Value
MOON/1001006	25/F/Ca	3	C	1	Cmax (ng/mL)	16300
					t1/2 (h)	12.1
					tmax (h)	2.98
MOON/1001007	25/F/Ca	1	A	1	AUC (h*ng/mL)	120000
					AUC(0-tlast)(h*ng/mL)	120000
					CL/F (mL/h)	3330
					Cmax (ng/mL)	14400
					t1/2 (h)	8.99
					tmax (h)	3.05
		3	C	1	AUC (h*ng/mL)	130000
					AUC(0-tlast)(h*ng/mL)	129000
					CL/F (mL/h)	3080
					Cmax (ng/mL)	16300
					t1/2 (h)	9.89
					tmax (h)	1.50
MOON/1001008	25/F/Ca	1	A	1	AUC (h*ng/mL)	195000
					AUC(0-tlast)(h*ng/mL)	194000
					CL/F (mL/h)	2060
					Cmax (ng/mL)	18000
					t1/2 (h)	11.9
					tmax (h)	1.50

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was calculated.
Value * was not considered for summary and inferential procedures.
Data: adpp Program: ppl.sas Output: l.16.2.5.pplv.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PPLv (Page 5 of 16)
Individual pharmacokinetic parameters
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL 2
Treatment sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Profile day	Parameter	Value
MOON/1001008	25/F/Ca	3	C	1	AUC (h*ng/mL)	186000
					AUC(0-tlast)(h*ng/mL)	185000
					CL/F (mL/h)	2150
					Cmax (ng/mL)	18700
					t1/2 (h)	15.5
					tmax (h)	2.00
MOON/1001009	25/F/Ca	1	A	1	AUC (h*ng/mL)	191000
					AUC(0-tlast)(h*ng/mL)	191000
					CL/F (mL/h)	2090
					Cmax (ng/mL)	22300
					t1/2 (h)	11.5
					tmax (h)	1.50
		3	C	1	AUC (h*ng/mL)	180000
					AUC(0-tlast)(h*ng/mL)	179000
					CL/F (mL/h)	2230
					Cmax (ng/mL)	17800
					t1/2 (h)	12.5
					tmax (h)	2.00
MOON/1001010	25/F/Ca	1	A	1	AUC (h*ng/mL)	174000
					AUC(0-tlast)(h*ng/mL)	174000
					CL/F (mL/h)	2290

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was calculated.
Value * was not considered for summary and inferential procedures.
Data: adpp Program: ppl.sas Output: l.16.2.5.pplv.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PPLv (Page 6 of 16)
Individual pharmacokinetic parameters
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL 2
Treatment sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Profile day	Parameter	Value
MOON/1001010	25/F/Ca	1	A	1	Cmax (ng/mL)	17500
					t1/2 (h)	9.37
					tmax (h)	1.50
		3	C	1	AUC (h*ng/mL)	192000
					AUC(0-tlast)(h*ng/mL)	192000
					CL/F (mL/h)	2080
					Cmax (ng/mL)	17500
					t1/2 (h)	11.2
					tmax (h)	1.52
MOON/1001011	25/F/Ca	1	A	1	AUC (h*ng/mL)	157000
					AUC(0-tlast)(h*ng/mL)	157000
					CL/F (mL/h)	2540
					Cmax (ng/mL)	18200
					t1/2 (h)	9.32
					tmax (h)	1.50
		3	C	1	AUC (h*ng/mL)	175000
					AUC(0-tlast)(h*ng/mL)	174000
					CL/F (mL/h)	2280
					Cmax (ng/mL)	18100
					t1/2 (h)	9.17
					tmax (h)	4.02

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was calculated.
Value * was not considered for summary and inferential procedures.
Data: adpp Program: ppl.sas Output: l.16.2.5.pplv.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PPLv (Page 7 of 16)
Individual pharmacokinetic parameters
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL 2
Treatment sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Profile day	Parameter	Value
MOON/1001012	25/F/Ca	1	A	1	AUC (h*ng/mL)	236000
					AUC(0-tlast)(h*ng/mL)	235000
					CL/F (mL/h)	1700
					Cmax (ng/mL)	16700
					t1/2 (h)	11.8
					tmax (h)	3.00
		3	C	1	AUC (h*ng/mL)	245000
					AUC(0-tlast)(h*ng/mL)	243000
					CL/F (mL/h)	1640
					Cmax (ng/mL)	18200
					t1/2 (h)	13.0
					tmax (h)	2.03
MOON/1001013	25/F/Ca	1	A	1	AUC (h*ng/mL)	161000
					AUC(0-tlast)(h*ng/mL)	160000
					CL/F (mL/h)	2490
					Cmax (ng/mL)	15700
					t1/2 (h)	9.90
					tmax (h)	3.00
		3	C	1	AUC (h*ng/mL)	170000
					AUC(0-tlast)(h*ng/mL)	169000
					CL/F (mL/h)	2360

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was calculated.
Value * was not considered for summary and inferential procedures.
Data: adpp Program: ppl.sas Output: l.16.2.5.pplv.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PPLv (Page 8 of 16)
Individual pharmacokinetic parameters
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL 2
Treatment sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Profile day	Parameter	Value
MOON/1001013	25/F/Ca	3	C	1	Cmax (ng/mL)	14100
					t1/2 (h)	11.3
					tmax (h)	2.98
MOON/1001014	25/F/Ca	1	A	1	AUC (h*ng/mL)	161000
					AUC(0-tlast)(h*ng/mL)	160000
					CL/F (mL/h)	2480
					Cmax (ng/mL)	14400
					t1/2 (h)	9.44
					tmax (h)	3.02
		3	C	1	AUC (h*ng/mL)	144000
					AUC(0-tlast)(h*ng/mL)	143000
					CL/F (mL/h)	2780
					Cmax (ng/mL)	16700
					t1/2 (h)	9.13
					tmax (h)	1.50
MOON/1001015	25/F/Ca	1	A	1	AUC (h*ng/mL)	140000
					AUC(0-tlast)(h*ng/mL)	140000
					CL/F (mL/h)	2860
					Cmax (ng/mL)	16300
					t1/2 (h)	8.40
					tmax (h)	3.00

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was calculated.
Value * was not considered for summary and inferential procedures.
Data: adpp Program: ppl.sas Output: l.16.2.5.pplv.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PPLv (Page 9 of 16)
Individual pharmacokinetic parameters
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL 2
Treatment sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Profile day	Parameter	Value
MOON/1001015	25/F/Ca	3	C	1	AUC (h*ng/mL)	144000
					AUC(0-tlast)(h*ng/mL)	142000
					CL/F (mL/h)	2780
					Cmax (ng/mL)	15000
					t1/2 (h)	7.29
					tmax (h)	2.02
MOON/1001016	25/F/Ca	1	A	1	AUC (h*ng/mL)	117000
					AUC(0-tlast)(h*ng/mL)	116000
					CL/F (mL/h)	3410
					Cmax (ng/mL)	16300
					t1/2 (h)	7.66
					tmax (h)	1.50
		3	C	1	AUC (h*ng/mL)	140000
					AUC(0-tlast)(h*ng/mL)	140000
					CL/F (mL/h)	2850
					Cmax (ng/mL)	17100
					t1/2 (h)	8.69
					tmax (h)	1.50
MOON/1001017	25/F/Ca	1	A	1	AUC (h*ng/mL)	219000
					AUC(0-tlast)(h*ng/mL)	218000
					CL/F (mL/h)	1830

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was calculated.
Value * was not considered for summary and inferential procedures.
Data: adpp Program: ppl.sas Output: l.16.2.5.pplv.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PPLv (Page 10 of 16)
Individual pharmacokinetic parameters
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL 2
Treatment sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Profile day	Parameter	Value
MOON/1001017	25/F/Ca	1	A	1	Cmax (ng/mL)	24900
					t1/2 (h)	8.99
					tmax (h)	3.00
		3	C	1	AUC (h*ng/mL)	207000
					AUC(0-tlast)(h*ng/mL)	207000
					CL/F (mL/h)	1930
					Cmax (ng/mL)	22500
					t1/2 (h)	11.3
					tmax (h)	4.00
MOON/1001018	25/F/Ca	1	A	1	AUC (h*ng/mL)	205000
					AUC(0-tlast)(h*ng/mL)	204000
					CL/F (mL/h)	1950
					Cmax (ng/mL)	22500
					t1/2 (h)	9.64
					tmax (h)	2.02
		3	C	1	AUC (h*ng/mL)	228000
					AUC(0-tlast)(h*ng/mL)	228000
					CL/F (mL/h)	1750
					Cmax (ng/mL)	22600
					t1/2 (h)	11.1
					tmax (h)	3.00

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was calculated.
Value * was not considered for summary and inferential procedures.
Data: adpp Program: ppl.sas Output: l.16.2.5.pplv.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PPLv (Page 11 of 16)
Individual pharmacokinetic parameters
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL 2
Treatment sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Profile day	Parameter	Value
MOON/1001019	25/F/Ca	1	A	1	AUC (h*ng/mL)	164000
					AUC(0-tlast)(h*ng/mL)	164000
					CL/F (mL/h)	2430
					Cmax (ng/mL)	19500
					t1/2 (h)	9.49
					tmax (h)	2.00
		3	C	1	AUC (h*ng/mL)	167000
					AUC(0-tlast)(h*ng/mL)	167000
					CL/F (mL/h)	2390
					Cmax (ng/mL)	19500
					t1/2 (h)	10.2
					tmax (h)	1.50
MOON/1001020	25/F/Ca	1	A	1	AUC (h*ng/mL)	126000
					AUC(0-tlast)(h*ng/mL)	125000
					CL/F (mL/h)	3160
					Cmax (ng/mL)	16200
					t1/2 (h)	7.37
					tmax (h)	1.50
		3	C	1	AUC (h*ng/mL)	126000
					AUC(0-tlast)(h*ng/mL)	125000
					CL/F (mL/h)	3180

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was calculated.
Value * was not considered for summary and inferential procedures.
Data: adpp Program: ppl.sas Output: l.16.2.5.pplv.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PPLv (Page 12 of 16)
Individual pharmacokinetic parameters
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL 2
Treatment sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Profile day	Parameter	Value
MOON/1001020	25/F/Ca	3	C	1	Cmax (ng/mL)	14700
					t1/2 (h)	7.18
					tmax (h)	3.00
MOON/1001021	25/F/Ca	1	A	1	AUC (h*ng/mL)	189000
					AUC(0-tlast)(h*ng/mL)	188000
					CL/F (mL/h)	2110
					Cmax (ng/mL)	16300
					t1/2 (h)	9.98
					tmax (h)	2.00
		3	C	1	AUC (h*ng/mL)	194000
					AUC(0-tlast)(h*ng/mL)	193000
					CL/F (mL/h)	2060
					Cmax (ng/mL)	19200
					t1/2 (h)	12.7
					tmax (h)	2.02
MOON/1001022	25/F/Ca	1	A	1	AUC (h*ng/mL)	320000
					AUC(0-tlast)(h*ng/mL)	319000
					CL/F (mL/h)	1250
					Cmax (ng/mL)	24400
					t1/2 (h)	12.9
					tmax (h)	1.50

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was calculated.
Value * was not considered for summary and inferential procedures.
Data: adpp Program: ppl.sas Output: l.16.2.5.pplv.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PPLv (Page 13 of 16)
Individual pharmacokinetic parameters
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL 2
Treatment sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Profile day	Parameter	Value
MOON/1001022	25/F/Ca	3	C	1	AUC (h*ng/mL)	275000
					AUC(0-tlast)(h*ng/mL)	273000
					CL/F (mL/h)	1450
					Cmax (ng/mL)	21400
					t1/2 (h)	13.7
					tmax (h)	3.00
MOON/1001023	25/F/Ca	1	A	1	AUC (h*ng/mL)	123000
					AUC(0-tlast)(h*ng/mL)	122000
					CL/F (mL/h)	3250
					Cmax (ng/mL)	15400
					t1/2 (h)	6.80
					tmax (h)	4.03
		3	C	1	AUC (h*ng/mL)	123000
					AUC(0-tlast)(h*ng/mL)	122000
					CL/F (mL/h)	3250
					Cmax (ng/mL)	14300
					t1/2 (h)	6.70
					tmax (h)	3.00
MOON/1001024	25/F/Ca	1	A	1	AUC (h*ng/mL)	171000
					AUC(0-tlast)(h*ng/mL)	171000
					CL/F (mL/h)	2340

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was calculated.
Value * was not considered for summary and inferential procedures.
Data: adpp Program: ppl.sas Output: l.16.2.5.pplv.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PPLv (Page 14 of 16)
Individual pharmacokinetic parameters
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL 2
Treatment sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Profile day	Parameter	Value
MOON/1001024	25/F/Ca	1	A	1	Cmax (ng/mL)	19500
					t1/2 (h)	9.40
					tmax (h)	1.50
		3	C	1	AUC (h*ng/mL)	206000
					AUC(0-tlast)(h*ng/mL)	205000
					CL/F (mL/h)	1940
					Cmax (ng/mL)	18400
					t1/2 (h)	12.7
					tmax (h)	3.00
MOON/1001025	25/F/Ca	1	A	1	AUC (h*ng/mL)	216000
					AUC(0-tlast)(h*ng/mL)	216000
					CL/F (mL/h)	1850
					Cmax (ng/mL)	15400
					t1/2 (h)	11.1
					tmax (h)	4.00
		3	C	1	AUC (h*ng/mL)	237000
					AUC(0-tlast)(h*ng/mL)	236000
					CL/F (mL/h)	1690
					Cmax (ng/mL)	21200
					t1/2 (h)	13.5
					tmax (h)	2.02

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was calculated.
Value * was not considered for summary and inferential procedures.
Data: adpp Program: ppl.sas Output: l.16.2.5.pplv.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PPLv (Page 15 of 16)
Individual pharmacokinetic parameters
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL 2
Treatment sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Profile day	Parameter	Value
MOON/1001026	25/F/Ca	1	A	1	AUC (h*ng/mL)	146000
					AUC(0-tlast)(h*ng/mL)	145000
					CL/F (mL/h)	2750
					Cmax (ng/mL)	15100
					t1/2 (h)	7.90
					tmax (h)	4.02
		3	C	1	AUC (h*ng/mL)	139000
					AUC(0-tlast)(h*ng/mL)	137000
					CL/F (mL/h)	2890
					Cmax (ng/mL)	15400
					t1/2 (h)	7.46
					tmax (h)	2.00
MOON/1001027	25/F/Ca	1	A	1	AUC (h*ng/mL)	165000
					AUC(0-tlast)(h*ng/mL)	164000
					CL/F (mL/h)	2430
					Cmax (ng/mL)	12900
					t1/2 (h)	9.30
					tmax (h)	4.00
		3	C	1	AUC (h*ng/mL)	171000
					AUC(0-tlast)(h*ng/mL)	171000
					CL/F (mL/h)	2330

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was calculated.
Value * was not considered for summary and inferential procedures.
Data: adpp Program: ppl.sas Output: l.16.2.5.pplv.txt
Fake Data/ Production Run on 11MAR2014:10:31

Listing 16.2.5-PPLv (Page 16 of 16)
Individual pharmacokinetic parameters
by compound, matrix, analyte and actual treatment
Analysis Set: All subjects

Compound: A , Matrix: PLASMA , Analyte: ANAL 2
Treatment sequence: A / B /C

Country/ Subject identifier	Age/ Sex/ Race	Period	Treatment Name	Profile day	Parameter	Value
MOON/1001027	25/F/Ca	3	C	1	Cmax (ng/mL)	23700
					t1/2 (h)	9.49
					tmax (h)	1.52
MOON/1001028	25/F/Ca	1	A	1	AUC (h*ng/mL)	246000
					AUC(0-tlast)(h*ng/mL)	244000
					CL/F (mL/h)	1630
					Cmax (ng/mL)	18700
					t1/2 (h)	13.1
					tmax (h)	1.50
		3	C	1	AUC (h*ng/mL)	231000
					AUC(0-tlast)(h*ng/mL)	230000
					CL/F (mL/h)	1730
					Cmax (ng/mL)	17000
					t1/2 (h)	13.5
					tmax (h)	3.00

Age/Sex/Race: F=Female, Ca=Caucasian.
NV: No Value was calculated.
Value * was not considered for summary and inferential procedures.
Data: adpp Program: ppl.sas Output: l.16.2.5.pplv.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Table 14.2-PCTScens (Page 1 of 6)
Summary statistics for PK concentrations
by compound, matrix, analyte and actual treatment
Analysis Set : PK analysis set

Compound: A , Matrix: PLASMA , Analyte: ANAL2 , Unit: ng/mL

Profile day	Dose reference id	Scheduled time point (h)	Statistic	Period 1 Treatment	Period 3 Treatment
1	1	0	N	28	27
			<LLOQ - n (%)	28 (100%)	27 (100%)
			Mean (SD)	20.4 (0.0419)	20.4 (0.0419)
			CV% mean	0.2	0.2
			Geo-mean	29.0	29.0
			CV% geo-mean	4.2	4.2
			Median		
			[Min; Max]		
		0.25	N	28	27
			<LLOQ - n (%)	7 (25%)	10 (37%)
			Mean (SD)	159 (131)	160 (121)
			CV% mean	82.2	76.1
			Geo-mean	101	96.9
			CV% geo-mean	107.8	114.1
			Median		
			[Min; Max]	[;488]	[;425]
		0.5	N	28	26
			<LLOQ - n (%)	1 (3.6%)	0 (0.0%)
			Mean (SD)	1970 (1470)	1760 (1350)
			CV% mean	74.7	0.8

n = number of non-missing observations including values<LLOQ.
<LLOQ - n (%) number and percentage of values < LLOQ (10ng/mL).
CV% geo-mean=(sqrt (exp (variance for log transformed data)-1))*100
Geo-mean: Geometric mean.
In case of values <LLOQ ,the Mean, SD CV% mean, Geo-mean, CV% geo-mean are adjusted for left-censored data at the LLOQ.
If no value is<LLOQ, descriptive summary statistics are presented.
Data: adpc Program: pcscens.sas Output: t.14.2.pctscens.txt
Fake Data/ Production Run on 11MAR2014:10:30

Study001

Table 14.2-PCTScens (Page 2 of 6)
Summary statistics for PK concentrations
by compound, matrix, analyte and actual treatment
Analysis Set : PK analysis set

Compound: A , Matrix: PLASMA , Analyte: ANAL2 , Unit: ng/mL

Profile day	Dose reference id	Scheduled time point (h)	Statistic	Period 1 Treatment	Period 3 Treatment
1	1	0.5	Geo-mean	1420	1210
			CV% geo-mean	104.1	1.3
			Median		1520
			[Min; Max]	[;5790]	[182;4550]
		1	N	28	26
			<LLOQ - n (%)	0 (0.0%)	0 (0.0%)
			Mean (SD)	9290 (5040)	9920 (4190)
			CV% mean	0.5	0.4
			Geo-mean	7770	8690
			CV% geo-mean	0.7	0.7
			Median	9140	10800
			[Min; Max]	[1850;18900]	[1870;16500]
		1.5	N	28	27
			<LLOQ - n (%)	0 (0.0%)	0 (0.0%)
			Mean (SD)	14200 (5650)	14600 (4940)
			CV% mean	0.4	0.3
			Geo-mean	13000	13500
			CV% geo-mean	0.5	0.4
			Median	15200	16300
			[Min; Max]	[4790;24400]	[4800;23700]

n = number of non-missing observations including values<LLOQ.
<LLOQ - n (%) number and percentage of values < LLOQ (10ng/mL).
CV% geo-mean=(sqrt (exp (variance for log transformed data)-1))*100
Geo-mean: Geometric mean.
In case of values <LLOQ ,the Mean, SD CV% mean, Geo-mean, CV% geo-mean are adjusted for left-censored data at the LLOQ.
If no value is<LLOQ, descriptive summary statistics are presented.
Data: adpc Program: pcscens.sas Output: t.14.2.pctscens.txt
Fake Data/ Production Run on 11MAR2014:10:30

Study001

Table 14.2-PCTScens (Page 3 of 6)
Summary statistics for PK concentrations
by compound, matrix, analyte and actual treatment
Analysis Set : PK analysis set

Compound: A , Matrix: PLASMA , Analyte: ANAL2 , Unit: ng/mL

Profile day	Dose reference id	Scheduled time point (h)	Statistic	Period 1 Treatment	Period 3 Treatment
1	1	2	N	28	27
			<LLOQ - n (%)	0 (0.0%)	0 (0.0%)
			Mean (SD)	15400 (4660)	16000 (3970)
			CV% mean	0.3	0.2
			Geo-mean	14700	15400
			CV% geo-mean	0.3	0.3
			Median	16200	16400
			[Min; Max]	[6960;26400]	[8420;21800]
		3	N	28	27
			<LLOQ - n (%)	0 (0.0%)	0 (0.0%)
			Mean (SD)	15700 (3790)	15900 (2620)
			CV% mean	0.2	0.2
			Geo-mean	15300	15700
			CV% geo-mean	0.3	0.2
			Median	15800	14900
			[Min; Max]	[7670;24900]	[11500;22600]
		4	N	28	27
			<LLOQ - n (%)	0 (0.0%)	0 (0.0%)
			Mean (SD)	14000 (2810)	14200 (3110)
			CV% mean	0.2	0.2

n = number of non-missing observations including values<LLOQ.
<LLOQ - n (%) number and percentage of values < LLOQ (10ng/mL).
CV% geo-mean=(sqrt (exp (variance for log transformed data)-1))*100
Geo-mean: Geometric mean.
In case of values <LLOQ ,the Mean, SD CV% mean, Geo-mean, CV% geo-mean are adjusted for left-censored data at the LLOQ.
If no value is<LLOQ, descriptive summary statistics are presented.
Data: adpc Program: pcscens.sas Output: t.14.2.pctscens.txt
Fake Data/ Production Run on 11MAR2014:10:30

Study001

Table 14.2-PCTScens (Page 4 of 6)
Summary statistics for PK concentrations
by compound, matrix, analyte and actual treatment
Analysis Set : PK analysis set

Compound: A , Matrix: PLASMA , Analyte: ANAL2 , Unit: ng/mL

Profile day	Dose reference id	Scheduled time point (h)	Statistic	Period 1 Treatment	Period 3 Treatment
1	1	4	Geo-mean	13700	13900
			CV% geo-mean	0.2	0.2
			Median	13500	13600
			[Min; Max]	[7920;22900]	[9880;22500]
		6	N	28	27
			<LLOQ - n (%)	0 (0.0%)	0 (0.0%)
			Mean (SD)	9780 (2280)	9650 (2070)
			CV% mean	0.2	0.2
			Geo-mean	9540	9440
			CV% geo-mean	0.2	0.2
			Median	9260	9420
			[Min; Max]	[5880;15200]	[6720;14000]
		8	N	28	27
			<LLOQ - n (%)	0 (0.0%)	0 (0.0%)
			Mean (SD)	7220 (1780)	7160 (1670)
			CV% mean	0.2	0.2
			Geo-mean	7010	6970
			CV% geo-mean	0.2	0.2
			Median	6820	7110
			[Min; Max]	[4490;11500]	[4580;10400]

n = number of non-missing observations including values<LLOQ.
<LLOQ - n (%) number and percentage of values < LLOQ (10ng/mL).
CV% geo-mean=(sqrt (exp (variance for log transformed data)-1))*100
Geo-mean: Geometric mean.
In case of values <LLOQ ,the Mean, SD CV% mean, Geo-mean, CV% geo-mean are adjusted for left-censored data at the LLOQ.
If no value is<LLOQ, descriptive summary statistics are presented.
Data: adpc Program: pcscens.sas Output: t.14.2.pctscens.txt
Fake Data/ Production Run on 11MAR2014:10:30

Study001

Table 14.2-PCTScens (Page 5 of 6)
Summary statistics for PK concentrations
by compound, matrix, analyte and actual treatment
Analysis Set : PK analysis set

Compound: A , Matrix: PLASMA , Analyte: ANAL2 , Unit: ng/mL

Profile day	Dose reference id	Scheduled time point (h)	Statistic	Period 1 Treatment	Period 3 Treatment
1	1	12	N	27	26
			<LLOQ - n (%)	0 (0.0%)	0 (0.0%)
			Mean (SD)	4440 (1310)	4580 (1160)
			CV% mean	0.3	0.3
			Geo-mean	4270	4440
			CV% geo-mean	0.3	0.3
			Median	4400	4580
			[Min; Max]	[2440;7980]	[2820;7050]
2	1	24	N	28	26
			<LLOQ - n (%)	0 (0.0%)	0 (0.0%)
			Mean (SD)	1730 (809)	1710 (687)
			CV% mean	0.5	0.4
			Geo-mean	1570	1590
			CV% geo-mean	0.5	0.4
			Median	1610	1640
			[Min; Max]	[805;4020]	[845;3300]
3	1	48	N	28	27
			<LLOQ - n (%)	0 (0.0%)	0 (0.0%)
			Mean (SD)	311 (223)	302 (192)
			CV% mean	0.7	0.6

n = number of non-missing observations including values<LLOQ.
<LLOQ - n (%) number and percentage of values < LLOQ (10ng/mL).
CV% geo-mean=(sqrt (exp (variance for log transformed data)-1))*100
Geo-mean: Geometric mean.
In case of values <LLOQ ,the Mean, SD CV% mean, Geo-mean, CV% geo-mean are adjusted for left-censored data at the LLOQ.
If no value is<LLOQ, descriptive summary statistics are presented.
Data: adpc Program: pcscens.sas Output: t.14.2.pctscens.txt
Fake Data/ Production Run on 11MAR2014:10:30

Study001

Table 14.2-PCTScens (Page 6 of 6)
Summary statistics for PK concentrations
by compound, matrix, analyte and actual treatment
Analysis Set : PK analysis set

Compound: A , Matrix: PLASMA , Analyte: ANAL2 , Unit: ng/mL

Profile day	Dose reference id	Scheduled time point (h)	Statistic	Period 1 Treatment	Period 3 Treatment
3	1	48	Geo-mean	251	248
			CV% geo-mean	0.7	0.7
			Median	264	262
			[Min; Max]	[83.2;928]	[69.1;762]
4	1	72	N	28	27
			<LLOQ - n (%)	4 (14%)	4 (15%)
			Mean (SD)	84.2 (60.3)	90.5 (57.1)
			CV% mean	71.6	63.0
			Geo-mean	65.4	72.0
			CV% geo-mean	72.2	72.5
			Median		
			[Min; Max]	[;247]	[;216]
5	1	96	N	28	27
			<LLOQ - n (%)	20 (71%)	13 (48%)
			Mean (SD)	51.8 (18.9)	46.9 (18.6)
			CV% mean	36.5	39.7
			Geo-mean	44.8	41.5
			CV% geo-mean	42.8	44.3
			Median		
			[Min; Max]	[;84.1]	[;86.9]

n = number of non-missing observations including values<LLOQ.
<LLOQ - n (%) number and percentage of values < LLOQ (10ng/mL).
CV% geo-mean=(sqrt (exp (variance for log transformed data)-1))*100
Geo-mean: Geometric mean.
In case of values <LLOQ ,the Mean, SD CV% mean, Geo-mean, CV% geo-mean are adjusted for left-censored data at the LLOQ.
If no value is<LLOQ, descriptive summary statistics are presented.
Data: adpc Program: pcscens.sas Output: t.14.2.pctscens.txt
Fake Data/ Production Run on 11MAR2014:10:30

Study001

Table 14.2-PPTS (Page 1 of 2)
Summary statistics for PK parameters
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set

Compound: A , Matrix: Plasma , Analyte: ANAL 2

Actual treatment	Period day	Statistic	AUC (h*ng/mL)	AUC(0-tlast) (h*ng/mL)	Cmax (ng/mL)
Period 1 Treatment	1	n	28	28	28
		Mean (SD)	179000 (51200)	178000 (51100)	17600 (3850)
		CV% mean	28.6	28.6	21.9
		Geo-mean	173000	172000	17200
		CV% geo-mean	27.3	27.3	23.5
		Median	168000	167000	16500
		[Min; Max]	[113000;320000]	[112000;319000]	[7920;26400]
Period 3 Treatment	1	n	27	27	27
		Mean (SD)	181000 (42800)	180000 (42600)	18100 (2940)
		CV% mean	23.7	23.7	16.3
		Geo-mean	176000	176000	17800
		CV% geo-mean	23.7	23.7	16.9
		Median	175000	174000	18100
		[Min; Max]	[123000;275000]	[122000;273000]	[11500;23700]

CV% = coefficient of variation (%)=sd/mean*100;
CV% geo-mean=(sqrt (exp (variance for log transformed data)-1))*100
Geo-mean: Geometric mean.
Geo-mean and CV% geo-mean not presented when the minimum value for a parameter is zero.
Data: adpp Program: pps.sas Output: t.14.2.ppts.txt
Fake Data/ Production Run on 11MAR2014:10:30

Study001

Table 14.2-PPTS (Page 2 of 2)
Summary statistics for PK parameters
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set

Compound: A , Matrix: Plasma , Analyte: ANAL 2

Actual treatment	Period day	Statistic	MRT (h)	t1/2 (h)	tmax (h)
Period 1 Treatment	1	n	28	28	28
		Mean (SD)	11.4 (2.02)	9.78 (1.80)	
		CV% mean	17.7	18.4	
		Geo-mean	11.2	9.62	
		CV% geo-mean	17.6	18.6	
		Median	11.2	9.42	2.01
		[Min; Max]	[8.34;15.4]	[6.66;13.1]	[1.50;4.03]
Period 3 Treatment	1	n	27	27	27
		Mean (SD)	11.4 (2.04)	10.7 (2.34)	
		CV% mean	17.9	21.9	
		Geo-mean	11.2	10.5	
		CV% geo-mean	18.2	23.0	
		Median	11.5	11.1	2.02
		[Min; Max]	[8.53;15.5]	[6.70;15.5]	[1.50;4.03]

CV% = coefficient of variation (%)=sd/mean*100;
CV% geo-mean=(sqrt (exp (variance for log transformed data)-1))*100
Geo-mean: Geometric mean.
Geo-mean and CV% geo-mean not presented when the minimum value for a parameter is zero.
Data: adpp Program: pps.sas Output: t.14.2.ppts.txt
Fake Data/ Production Run on 11MAR2014:10:30

Study001

Table 14.2-PCTS (Page 1 of 6)
Summary statistics for PK concentrations
by compound, matrix, analyte and actual treatment
Analysis Set : PK analysis set

Compound: A , Matrix: PLASMA , Analyte: ANAL2 , Unit: ng/mL

Profile day	Dose reference id	Scheduled time point (h)	Statistic	Period 1 Treatment	Period 3 Treatment
1	1	0	n	28	27
			Mean (SD)	0.00 (0.00)	0.00 (0.00)
			CV% mean		
			Geo-mean		
			CV% geo-mean		
			Median	0.00	0.00
			[Min; Max]	[0.00;0.00]	[0.00;0.00]
		0.25	n	28	27
			Mean (SD)	111 (137)	89.9 (126)
			CV% mean	123.5	140.4
			Geo-mean		
			CV% geo-mean		
			Median	55.6	35.9
			[Min; Max]	[0.00;488]	[0.00;425]
		0.5	n	28	26
			Mean (SD)	1890 (1530)	1760 (1350)
			CV% mean	80.6	76.7
			Geo-mean	1210	
			CV% geo-mean	125.9	
			Median	1490	1520

CV% = coefficient of variation (%)=sd/mean*100;
CV% geo-mean=(sqrt (exp (variance for log transformed data)-1))*100
Geo-mean: Geometric mean.
Geo-mean and CV% geo-mean not presented when the minimum concentration is zero at respective timepoint.
Values <LLOQ (10ng/mL) were considered as zero in descriptive statistics calculation.
Data: adpc Program: pcs.sas Output: t14.2.pcts.txt
Fake Data/ Production Run on 11MAR2014:10:30

Study001

Table 14.2-PCTS (Page 2 of 6)
Summary statistics for PK concentrations
by compound, matrix, analyte and actual treatment
Analysis Set : PK analysis set

Compound: A , Matrix: PLASMA , Analyte: ANAL2 , Unit: ng/mL

Profile day	Dose reference id	Scheduled time point (h)	Statistic	Period 1 Treatment	Period 3 Treatment
1	1	0.5	[Min; Max]	[0.00;5790]	[182;4550]
		1	n	28	26
			Mean (SD)	9290 (5040)	9920 (4190)
			CV% mean	54.2	42.3
			Geo-mean	7770	8690
			CV% geo-mean	73.2	65.4
			Median	9140	10800
			[Min; Max]	[1850;18900]	[1870;16500]
		1.5	n	28	27
			Mean (SD)	14200 (5650)	14600 (4940)
			CV% mean	39.7	34.0
			Geo-mean	13000	13500
			CV% geo-mean	47.4	44.7
			Median	15200	16300
			[Min; Max]	[4790;24400]	[4800;23700]
		2	n	28	27
			Mean (SD)	15400 (4660)	16000 (3970)
			CV% mean	30.3	24.8
			Geo-mean	14700	15400

CV% = coefficient of variation (%)=sd/mean*100;
CV% geo-mean=(sqrt (exp (variance for log transformed data)-1))*100
Geo-mean: Geometric mean.
Geo-mean and CV% geo-mean not presented when the minimum concentration is zero at respective timepoint.
Values <LLOQ (10ng/mL) were considered as zero in descriptive statistics calculation.
Data: adpc Program: pcs.sas Output: t14.2.pcts.txt
Fake Data/ Production Run on 11MAR2014:10:30

Study001

Table 14.2-PCTS (Page 3 of 6)
Summary statistics for PK concentrations
by compound, matrix, analyte and actual treatment
Analysis Set : PK analysis set

Compound: A , Matrix: PLASMA , Analyte: ANAL2 , Unit: ng/mL

Profile day	Dose reference id	Scheduled time point (h)	Statistic	Period 1 Treatment	Period 3 Treatment
1	1	2	CV% geo-mean	33.9	27.8
			Median	16200	16400
			[Min; Max]	[6960;26400]	[8420;21800]
		3	n	28	27
			Mean (SD)	15700 (3790)	15900 (2620)
			CV% mean	24.1	16.5
			Geo-mean	15300	15700
			CV% geo-mean	25.5	15.9
			Median	15800	14900
			[Min; Max]	[7670;24900]	[11500;22600]
		4	n	28	27
			Mean (SD)	14000 (2810)	14200 (3110)
			CV% mean	20.1	22.0
			Geo-mean	13700	13900
			CV% geo-mean	19.5	21.1
			Median	13500	13600
			[Min; Max]	[7920;22900]	[9880;22500]
		6	n	28	27
			Mean (SD)	9780 (2280)	9650 (2070)

CV% = coefficient of variation (%)=sd/mean*100;
CV% geo-mean=(sqrt (exp (variance for log transformed data)-1))*100
Geo-mean: Geometric mean.
Geo-mean and CV% geo-mean not presented when the minimum concentration is zero at respective timepoint.
Values <LLOQ (10ng/mL) were considered as zero in descriptive statistics calculation.
Data: adpc Program: pcs.sas Output: t14.2.pcts.txt
Fake Data/ Production Run on 11MAR2014:10:30

Study001

Table 14.2-PCTS (Page 4 of 6)
Summary statistics for PK concentrations
by compound, matrix, analyte and actual treatment
Analysis Set : PK analysis set

Compound: A , Matrix: PLASMA , Analyte: ANAL2 , Unit: ng/mL

Profile day	Dose reference id	Scheduled time point (h)	Statistic	Period 1 Treatment	Period 3 Treatment
1	1	6	CV% mean	23.3	21.5
			Geo-mean	9540	9440
			CV% geo-mean	22.9	21.2
			Median	9260	9420
			[Min; Max]	[5880;15200]	[6720;14000]
		8	n	28	27
			Mean (SD)	7220 (1780)	7160 (1670)
			CV% mean	24.7	23.4
			Geo-mean	7010	6970
			CV% geo-mean	24.6	23.6
			Median	6820	7110
			[Min; Max]	[4490;11500]	[4580;10400]
		12	n	27	26
			Mean (SD)	4440 (1310)	4580 (1160)
			CV% mean	29.5	25.3
			Geo-mean	4270	4440
			CV% geo-mean	28.7	25.9
			Median	4400	4580
			[Min; Max]	[2440;7980]	[2820;7050]

CV% = coefficient of variation (%)=sd/mean*100;
CV% geo-mean=(sqrt (exp (variance for log transformed data)-1))*100
Geo-mean: Geometric mean.
Geo-mean and CV% geo-mean not presented when the minimum concentration is zero at respective timepoint.
Values <LLOQ (10ng/mL) were considered as zero in descriptive statistics calculation.
Data: adpc Program: pcs.sas Output: t14.2.pcts.txt
Fake Data/ Production Run on 11MAR2014:10:30

Study001

Table 14.2-PCTS (Page 5 of 6)
Summary statistics for PK concentrations
by compound, matrix, analyte and actual treatment
Analysis Set : PK analysis set

Compound: A , Matrix: PLASMA , Analyte: ANAL2 , Unit: ng/mL

Profile day	Dose reference id	Scheduled time point (h)	Statistic	Period 1 Treatment	Period 3 Treatment
2	1	24	n	28	26
			Mean (SD)	1730 (809)	1710 (687)
			CV% mean	46.8	40.1
			Geo-mean	1570	1590
			CV% geo-mean	46.2	41.5
			Median	1610	1640
			[Min; Max]	[805;4020]	[845;3300]
3	1	48	n	28	27
			Mean (SD)	311 (223)	302 (192)
			CV% mean	71.6	63.5
			Geo-mean	251	248
			CV% geo-mean	74.6	73.3
			Median	264	262
			[Min; Max]	[83.2;928]	[69.1;762]
4	1	72	n	28	27
			Mean (SD)	69.9 (65.0)	75.4 (63.5)
			CV% mean	93.0	84.2
			Geo-mean		
			CV% geo-mean		
			Median	52.8	57.2

CV% = coefficient of variation (%)=sd/mean*100;
CV% geo-mean=(sqrt (exp (variance for log transformed data)-1))*100
Geo-mean: Geometric mean.
Geo-mean and CV% geo-mean not presented when the minimum concentration is zero at respective timepoint.
Values <LLOQ (10ng/mL) were considered as zero in descriptive statistics calculation.
Data: adpc Program: pcs.sas Output: t14.2.pcts.txt
Fake Data/ Production Run on 11MAR2014:10:30

Study001

Table 14.2-PCTS (Page 6 of 6)
Summary statistics for PK concentrations
by compound, matrix, analyte and actual treatment
Analysis Set : PK analysis set

Compound: A , Matrix: PLASMA , Analyte: ANAL2 , Unit: ng/mL

Profile day	Dose reference id	Scheduled time point (h)	Statistic	Period 1 Treatment	Period 3 Treatment
4	1	72	[Min; Max]	[0.00;247]	[0.00;216]
5	1	96	n	28	27
			Mean (SD)	13.4 (24.7)	23.0 (27.0)
			CV% mean	184.1	117.6
			Geo-mean		
			CV% geo-mean		
			Median	0.00	20.3
			[Min; Max]	[0.00;84.1]	[0.00;86.9]

CV% = coefficient of variation (%)=sd/mean*100;
CV% geo-mean=(sqrt (exp (variance for log transformed data)-1))*100
Geo-mean: Geometric mean.
Geo-mean and CV% geo-mean not presented when the minimum concentration is zero at respective timepoint.
Values <LLOQ (10ng/mL) were considered as zero in descriptive statistics calculation.
Data: adpc Program: pcs.sas Output: t14.2.pcts.txt
Fake Data/ Production Run on 11MAR2014:10:30

Study001

Figure 11-PCFS (Page 1 of 1)
Arithmetic mean (SD) concentration-time plot per treatment (overlaying) and analyte (separately)
Analysis Set: PK analysis set

Compound: A , Matrix: PLASMA , Analyte: ANAL2



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f11.pcfs.rtf
Fake Data/ Production Run on 11MAR2014:10:29

Study001

Table 11-PPTS
Summary statistics for PK parameters
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set

Compound: A , Matrix: Plasma , Analyte: ANAL 2

Actual treatment	Period day	Statistic	AUC (h*ng/mL)	AUC(0-tlast) (h*ng/mL)	Cmax (ng/mL)
Period 1 Treatment	1	n	28	28	28
		Mean (SD)	179000 (51200)	178000 (51100)	17600 (3850)
		CV% mean	28.6	28.6	21.9
		Geo-mean	173000	172000	17200
		CV% geo-mean	27.3	27.3	23.5
		Median	168000	167000	16500
		[Min; Max]	[113000;320000]	[112000;319000]	[7920;26400]
Period 3 Treatment	1	n	27	27	27
		Mean (SD)	181000 (42800)	180000 (42600)	18100 (2940)
		CV% mean	23.7	23.7	16.3
		Geo-mean	176000	176000	17800
		CV% geo-mean	23.7	23.7	16.9
		Median	175000	174000	18100
		[Min; Max]	[123000;275000]	[122000;273000]	[11500;23700]

Compound: A , Matrix: Plasma , Analyte: ANAL 2

Actual treatment	Period day	Statistic	MRT (h)	t1/2 (h)	tmax (h)
Period 1 Treatment	1	n	28	28	28
		Mean (SD)	11.4 (2.02)	9.78 (1.80)	
		CV% mean	17.7	18.4	
		Geo-mean	11.2	9.62	
		CV% geo-mean	17.6	18.6	
		Median	11.2	9.42	2.01
		[Min; Max]	[8.34;15.4]	[6.66;13.1]	[1.50;4.03]
Period 3 Treatment	1	n	27	27	27
		Mean (SD)	11.4 (2.04)	10.7 (2.34)	
		CV% mean	17.9	21.9	
		Geo-mean	11.2	10.5	
		CV% geo-mean	18.2	23.0	
		Median	11.5	11.1	2.02
		[Min; Max]	[8.53;15.5]	[6.70;15.5]	[1.50;4.03]

CV% = coefficient of variation (%)=sd/mean*100;
CV% geo-mean=(sqrt (exp (variance for log transformed data)-1))*100
Geo-mean: Geometric mean.
Geo-mean and CV% geo-mean not presented when the minimum value for a parameter is zero.
Data: adpp Program: pps.sas Output: t11.ppts.rtf
Fake Data/ Production Run on 11MAR2014:10:30

Study001

Figure 14.2-PCFS (Page 1 of 1)
Arithmetic mean (SD) concentration-time plot per treatment (overlaying) and analyte (separately)
Analysis Set: PK analysis set

Compound: A , Matrix: PLASMA , Analyte: ANAL2



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f14.2.pcfs.txt
Fake Data/ Production Run on 11MAR2014:10:30

Study001

Figure 16.2.5-PCFI (Page 1 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001001



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 2 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001002



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 3 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001003



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 4 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001004



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 5 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001005



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 6 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001006



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 7 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001007



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 8 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001008



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 9 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001009



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 10 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001010



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 11 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001011



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 12 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001012



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 13 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001013



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 14 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001014



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 15 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001015



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 16 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001016



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 17 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001017



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 18 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001018



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 19 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001019



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 20 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001020



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 21 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001021



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 22 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001022



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 23 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001023



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 24 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001024



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 25 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001025



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 26 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001026



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 27 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001027



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFI (Page 28 of 28)
Individual concentration-time profiles per treatment (Part II)
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Subject: MOON/1001028



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfi.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFO (Page 1 of 2)
Overlaying individual concentration-time profiles
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment: A



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfo.txt
Fake Data/ Production Run on 11MAR2014:10:31

Study001

Figure 16.2.5-PCFO (Page 2 of 2)
Overlaying individual concentration-time profiles
by compound, matrix, analyte and actual treatment
Analysis Set: PK analysis set
Compound: A , Matrix: PLASMA , Analyte: ANAL2
Treatment: C



Values <LLOQ (10ng/mL) were considered as zero.
Data: adpc Program: rep_graph.sas Output: f.16.2.5.pcfo.txt
Fake Data/ Production Run on 11MAR2014:10:31